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resumo 
 
 
A engenharia de tecidos combina células humanos, materiais e 
engenharia de modo a induzir respostas biológicas com o objetivo de 
proporcionar uma regeneração rápida e correta do tecido danificado. O 
uso de matrizes tridimensionais (3D) para suportar o crescimento 
celular, ao contrário dos convencionais materiais 2D, é de grande 
importância para a simulação da organização estrutural de tecidos 
biológicos. Outros aspetos da matriz extracelular (ECM), para além da 
sua arquitetura são conhecidos por afetar a resposta celular. Fatores 
biomecânicos apresentados às células através das proteínas da ECM 
influenciam a adesão celular e fenómenos tais como manutenção do 
fenótipo, diferenciação celular e proliferação. Estudos in vitro muitas 
vezes falham na apresentação de fatores fisiológicos que incluem 
dinâmica de fluidos, o qual pode levar a uma correta oxigenação do 
biomaterial com células incorporadas, bem como a fenómenos de 
mecanotransdução. Neste trabalho, propomos um sistema que revela o 
efeito de 32 combinações de proteínas da ECM na adesão e expressão 
da alcalina fosfatasse (ALP) em células estaminais derivadas da coluna 
óssea (MSCs), tanto em ambiente estático como dinâmico. Um 
bioreator foi desenhado de modo a permitir um estudo high-throughput, 
para que fossem analisadas 32 combinações biomaterial-célula 
simultaneamente. Este bioreactor foi construído a partir de material de 
laboratório comum e de baixo custo (incluindo tubos e seringas 
descartáveis). As MSCs foram semeadas em scaffolds de quitosano 
poroso, modificado covalentemente com proteínas da ECM do osso, 
assim como proteínas responsáveis por contacto célula-célula e 
componentes do esmalte. Uma análise fatorial permitiu correlacionar a 
presença das várias combinações proteicas com melhor adesão celular 
ao biomaterial, assim como uma expressão de ALP após 24 horas e 5 
dias de cultura. Os dados foram analisados tanto para ambiente 
estático, como dinâmico na presença de um pequeno fluxo, 
previamente comprovado como potenciador da diferenciação 
osteogénica de MSCs. O sistema desenvolvido foi útil na interpretação 
da grande complexidade das interações célula-ECM, e poderá ter 
possível aplicação no desenvolvimento de biomateriais para 
regeneração óssea, bem como em futuras aplicações como modelos de 
doença.  . 
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abstract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tissue engineering combines human cells, materials and engineering to 
induce biological responses seeking the rapid and accurate healing of 
damaged tissues. The use of three-dimensional (3D) matrices to support 
cellular growth, in opposition to traditionally used two dimensional (2D) 
materials, are of utmost importance to emulate the structural organization of 
biological tissues. Other aspects of the extracellular matrix (ECM) beyond its 
architecture are known to affect cell response. The biochemical cues 
presented to cells by ECM proteins influence cell adhesion and phenomena as 
cell phenotype maintenance, cell differentiation and proliferation. In vitro 
studies often lack physiological-like cues that include slow fluid dynamics, 
which may impair the correct oxygenation of the biomaterial-cells construct. 
Here, we engineered a system to disclose the effect of 32 different ECM 
protein combinations on the adhesion and alkaline phosphatase (ALP) 
expression of bone marrow-derived mesenchymal stem cells (MSCs), both 
under static and flow perfusion conditions. A novel bioreactor was designed to 
enable a high-throughput study, that allowed to withdraw data from 32 
biomaterial-cell combinations in one single test. The bioreactor was assembled 
from widely available affordable labware (including plastic tubes and 
disposable syringes). MSCs were seeded on chitosan porous scaffolds 
covalently modified with bone ECM proteins, as well as cell-cell contact 
proteins and enamel components. A factorial analysis study allowed 
correlating the presence of single and combinations of proteins with improved 
cell adhesion to biomaterials, as well as improved ALP quantification after 24 
hours and 5 days of culture. The data was analyzed both for static culture 
conditions, as well as in the presence of a slow perfusion rate, previously 
shown to potentiate MSCs osteogenic differentiation. The developed system 
has proven to be useful in the interpretation of the wide complexity of cells-
ECM interactions, and may find application in the development of biomaterials 
for tissue regeneration or as disease model platforms. 
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1. Introduction 
Bone physiology involves the coordinated regulation of a myriad of biological processes 
that lead to tissue development, homeostasis and repair upon trauma [1]. The regeneration 
process for bone, can thus be highly complicated to emulate, since several cues contribute 
to this niche. Some of these cues are: composition of bone’s soluble microenvironment, 
extracellular matrix (ECM) insoluble proteins and glycoprotein composition and renewal, 
cell-cell and cell-ECM interactions, the role of mechanical stimulation, or recent trends as 
the role of microRNA. The understanding of these cues has inspired the design of a 
plethora of bone regeneration approaches [2]. It is estimated that by with increasing obesity 
and poor physical activity, bone related injuries are going to duplicate, so there is a 
growing need for effective and efficient regeneration methods [3].  
The application of concepts learnt from nature for the emulation of the structure and 
physiology of healthy bone requires a careful approach: in general, the effect of 
(bio)chemical (e.g. presence of soluble cytokines, as bone morphogenic proteins – BMPs), 
structural and physical properties (e.g. different biomaterials chemistries), along with 
external mechanical stimuli (e.g. compressive stress or flow perfusion) on bone 
regeneration strategies have been explored in a unifactorial fashion. The same route has 
been taken for the design of biomaterials and tissue regeneration strategies. Nonetheless, 
one must not forget that bone is a complex, dynamic and intricate system, in which 
different biological processes and structural characteristics are proved to play 
complementary roles towards the successful regeneration and maintenance of bone’s 
healthy behavior [1]. Additionally, the possible role of some components of bone – 
including the immune cells crosstalk or the role of hematopoietic stem cells [4] - are still in 
need of study. While the understanding of individual distinctive biological processes and 
structural features of bone biology are crucial to develop new proof-of-concept therapies 
based on tissue engineering approaches, bone must not be overlooked as a dynamic and 
complex system in which regulated crosstalk occurs involving, simultaneously, different 
processes.  
The advent of stem cell biology, as well as the progressive know-how on the structural, 
biophysical and biochemical role of the extracellular matrix (ECM) components and the 
scrutiny of immune cells crosstalk supported recent advances in the design of biomaterials 
targeting bone regeneration [5]. The acknowledgement of such complexity may be an 
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effective manner to pave the way for the design of multifactorial strategies targeting bone 
regeneration and disease treatment. Some studies have approached aspects as crosstalk 
between different cell types (including mineral-forming cells, reabsorption cells, immune 
cells and vascular cells) [6,7], the combinatorial role of ECM proteins [8,9], the effect of 
physical factors as biomaterials stiffness and viscoelasticity [9], as well as the role of 
extrinsic mechanical forces actuating in the native bone (e.g., compression and shear 
stress) [10].  
As a way to understand the current design of finely tuned biomaterials and regeneration 
strategies, developed to allow close-to-native regeneration, this Review focuses on (i) the 
description of the most well-known phenomena of bone biology and, in a second part, (ii) 
on the description of studies that used a multifactorial approach to design bioinspired tissue 
engineering strategies based on the integration of diverse aspects of bone biology. 
 
2. A Macroscopic View of Bone 
Bone is the anatomic structure responsible for the movement, protection, maintenance of 
mineral homeostasis and structure of the human body. In a fully-grown adult, this structure 
is composed of 206 individual bones (excluding the sesamoid bones), which are 
interconnected to compose the skeleton [11]. The bones of the human body are divided in 
five major categories, which include long (e.g. clavicles, raddi, metacarpals, tibiae, 
phalanges, femurs, humeri, metatarsals, fibulae and ulnae), short (e.g. patellae, tarsal and 
carpal), flat (skull, sternum, mandible, ribs and scapulae), irregular (e.g. vertebrae, coccyx, 
sacrum and hyoid) and sesamoid bones (patella) [12]. 
Bone tissue is constituted by both cortical/compact bone, which is dense and solid, and 
trabecular/cancellous bone, which contains a spongeus-like structure. They are both 
composed of osteons [13]. The ratio of these two bone types varies according to its 
anatomical site (e.g. femoral head as a ratio of 50:50 cortical to trabecular; vertebra has a 
25:75; radial diaphysis is 95:5; and overall, the human skeleton is composed of the 80:20) 
[14].  
 
3.  Mechanisms of Bone Development and Repair 
During mammals’ fetal development and natural bone repair upon injury, bone formation 
is achieved through two processes: intramembranous and endochondral ossification. In 
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intramembranous ossification, mesenchymal stem cells recruited to the injury site 
differentiate into osteoblasts, forming the flat skull bones [1]. The primary structure for 
these two mechanisms to occur is the woven (or immature hollow) bone, that is readily 
replaced by the lamellar/secondary bone (parallel fibrils deposited in opposite directions) 
[15] This structure does not appear only in the fetal life, but every time a bone has a 
fracture, and this process continuously repeats itself (bone substitution) [15]. The 
formation of lamellar bone occurs at a much slower rate than that of woven bone [16]. 
3.1. Intramembranous bone formation 
In intramembranous ossification, mesenchymal stem cells (MSCs) present in mesenchyme 
or in the medullary cavity (caused by a bone injury) develop into osteoblasts. In fetal 
development, this process is mainly responsible for the formation of the flat skull bones 
and in some parts of the clavicles [17]. Unlike in endochondral ossification, bone is formed 
without a cartilaginous intermediate. The formation of a nidus – a cluster of 
undifferentiated MSCs – is the starting point for the intramembranous ossification process. 
The cells in these clusters stop their proliferation and develop into osteoprogenitor cells 
which, eventually, develop into osteoblasts [17]. This differentiation occurs from a pre-
osteoblast to osteoblast lineage [18]. Runx2 is the transcription factor responsible for the 
osteoblast differentiation [19,20]. After their differentiation, osteoblasts produce a non-
mineralized type-I collagen-rich fibrillar extracellular matrix (ECM): the osteoid. While 
entrapped in this matrix, osteoblasts differentiate into mature osteocytes, and the matrix is 
further mineralized. The described mechanism is also the backbone for the bone formation 
of the subperiosteal bone, thus, being the process behind the woven and lamellar bone type 
formation in this region [21]. understanding schematic representation of the 
intramembranous ossification process can be found in Figure 1.  
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Figure 1-Schematic representation of the matrix base for intramembranous ossification to 
occur. The MSCs condense and produce osteoblasts, that mineralize the bone matrix. They 
line the surfaces of the bone that is growing and continuously produce the bone matrix by 
apposition. No cartilage proceeds the formation of this bone type. Taken from Gilbert, S. 
F. (2003) [22]  
3.2. Endochondral ossification 
In endochondral ossification chondrocytes from the surrounding cartilage form a matrix 
template, which is called the growth plane, and only then do they differentiate into the 
other bone structures [19]. When chondrocytes’ morphology is round, they synthesize type 
II collagen [23] and then form a columnar layer and become pre-hypertrophic. They 
eventually differentiate in post-mitotic hypertrophic cells, which express type X collagen, 
mineralizing the surrounding matrix, and thus, forming the bone structure [24]. During the 
bone formation process, there are various cycles of death of the hypertrophic chondrocytes 
as well as invasion of the blood vessels, leading to the replacement of the matrix (collagen) 
by the trabecular bone, also known as primary spongiosa [25]. As the process continues, 
the trabecular bone is resorbed, and the center is split into different plates, and then this 
whole process is repeated (if chondrocytes are present in the plates) [25]. These cells act as 
a natural support for the formation of the primary bone structure [25]. The adequate 
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differentiation of chondrocytes into the hypertrophic phenotype is of extreme importance 
for the genesis and proliferation of bone tissue [25]. For a more visual comprehension of 
the whole process, please see figure 2.  
 
Figure 2 – Schematic representation of the chronological steps occurring during 
endochondral ossification. Taken from Nishimura et al. (2012) [26] 
For the formation of bone during the endochondral ossification process, some conditions 
must be met, which include: 
• The presence of the Sox Trio: Sox9/5/6. These molecules are responsible for the 
differentiation of MSCs into chondrogenic phenotype, as well as for the regulation of the 
expression of critical genes for the formation of the cartilaginous matrix [25,26]; 
• The fibroblast growth factors FGF receptor3, a membrane-spanning tyrosine kinase 
receptor expressed by chondrocytes, that has a domain to bind extracellular ligands, that 
binds (FGFs) and thus, initiates the receptor’s autophosphorylation, as well as the 
stimulation of the tyrosine kinase activity, leading to the inhibition of proliferation and 
growth of chondrocytes [27,28];  
• The bone morphogenic proteins (BMPs), which are responsible for the formation of 
mesenchymal condensations and formation of joints, in an initial stage of the endochondral 
ossification. After condensation, when long bones are already formed, BMP-2, -3, -4, -5 
and -7 are expressed in the perichondrium, BMP-2 and -6 are expressed in the hypertrophic 
chondrocytes, and BMP7 on proliferative chondrocytes. BMPs positively regulate 
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chondrocyte proliferation and negatively modulate chondrocyte terminal differentiation 
[28,29]; 
• The parathyroid hormone-related peptide, which binds and activates the receptor 
PTH/PTHrP. This receptor is also activated by the parathyroid hormone (main regulator of 
calcium/phosphate metabolism and remodulation of the bone). This way, the PTH/PTHrP 
complex acts as a main regulator of bone development and mineral ion homeostasis. The 
PTH peptide acts by maturing the immature chondrocytes to a mature hypertrophic 
chondrocyte; when the chondrocytes express PTHrP or an activated form of the receptor, a 
decrease on the cartilage maturation and increase in bone formation is observed [30]; 
• Indian hedgehog homolog (Ihh), a protein present in the embryogenic patterning, 
controls the endochondral bone formation by inhibiting the differentiation of hypertrophic 
chondrocytes, therefore delaying the mineralization of the matrix. This leads to an increase 
of PTHrP in the growth plate, when the PTHrP pathway is present. Ihh also acts as a 
chondrocyte proliferation stimulator, in a PTHrP-independent pathway [31]; 
• Runt related transcription factor 2 (Runx2), Runx3 and core-binding factor beta 
subunit (CBFβ). These three transcription factors have been described in the literature as 
promoters of chondrocytic hypertrophy, complementing each other in the process [32,33]; 
• The proteins HIF-1α (hypoxia-inducible factor-1) and VEGF (vascular endothelial 
growth factor). These two factors are very important for bone vascularization, since HIF-
1α acts by mediating hypoxic responses, allowing the survival of chondrocytes, and targets 
VEGF. VEGF is responsible for the stimulation of angiogenesis and vasculogenesis, and 
the restoration of the oxygen supply in hypoxic conditions. It is hypothesized that these 
two proteins act together in a pathway that regulates chondrocytes survival [34,35]. 
 
Stem cells osteogenic differentiation, that occurs in both ossification pathways, and are 
commonly targeted in tissue engineering, is divided in three main stages: (i) peak in cell 
number; (ii) cellular differentiation (with the first: step expression and transcription of 
alkaline phosphatase); (iii) and a terminal step: expression of osteocalcin and osteopontin 
[36]. In the human body, bone marrow MSCs reside in a specific niche composed of a 
large variety of support cells (hematopoietic progenitors; osteoclasts, immune cells and 
blood cells). This niche was first defined by Schofield, in 1908 [37]. The osteogenic 
differentiation of MSCs is influenced by factors secreted by osteoblasts and osteocytes 
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[38]. This phenomenon occurs through a communication network amongst two bone cells 
types - osteoblasts and osteocytes - that enhance a response in the MSCs, when these two 
bone cell types are in contact [38]. In vitro, the co-culture of MSCs with osteocytes 
showed greater osteodifferentation than the ones with osteoblasts, indicating that 
osteocytes induce MSCs’ osteogenesis more effectively than osteoblasts [38]. On the other 
hand, osteoblasts helped the proliferation of the MSCs [38].  The in vivo interactions 
between both cell types, as well as other cells belonging to the bone, are reviewed in more 
detail in the Section 5. The know-how acquired from such studies shows the importance of 
the presence of different cell types for stem cell differentiation and growth.  
 
4. Adult bone physiology 
In adult humans, bone is formed in two ways: longitudinal and radial growth [1]. These 
phenomena happen during the childhood and adolescence period. Modeling occurs during 
the first years of life of the individual, by response to physiological or mechanical factors. 
This is achieved by the action of the bone osteoprogenitor-derived cells: osteoblasts and 
osteoclasts (see section 5) [38]. Bone morphogenesis regulated by exposure to mechanical 
challenges is reviewed in more detail in Section 7, where the Frost’s “Mechanostat 
Theory” is explored, as well as its related biochemical signaling. Also, the role of cell 
types and their crosstalk during bone healthy state maintenance and upon trauma are 
reviewed in Section 5 and further ahead on this section. 
To form and maintain the complex and functional skeleton structure, bone tissues 
undergoes continuous remodeling during the whole life of adult individuals [1]. This 
process is related to the increasing fragility of bone throughout life, which leads to the 
necessity of the creation of new functional bone, allowing for the maintenance of the 
structural stability of the human body [11,12]. Bone remodeling is increased during adults’ 
middle age and happens in four stages: activation (activation and recruitment of 
osteoprogenitor cells), resorption (resorption of the osteoprogenitor cells by osteoclasts), 
reversal (transitional phase from bone resorption to bone formation) and formation (matrix 
synthesis by osteoblasts) [1,39]. A detailed explanation of the previously mentioned phases 
is provided in a review paper by Clarke et al. (1938) [1]. 
During bone resorption, osteoclasts act by removing the “old bone” packets; afterwards, 
new synthesized matrix is created, along with mineralized tissue [1]. Bone formation and 
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degradation are tightly kept in equilibrium throughout humans’ life by the bone 
homeostasis and remodeling process [1]. Osteoclasts (the promotors of bone resorption) 
and osteoblasts (with a role of bone formations) are the main mediators of this process [1]. 
The bone unit responsible to maintain this equilibrium is the basic multicellular unit 
(BMU), composed by osteoclasts, osteoblasts, connective tissue, nerves and blood vessels 
[40]. 
4.1. Bone Healing: tissue response upon injury 
Since bone is the main structure of our body, it is important to have a system that 
guaranties its maintenance and integrity [11]. Its healing upon fracture, avoiding the 
formation of scar tissues, is of utmost importance, so the function of bone is not 
compromised [12]. Fractures are the most common large-organ, traumatic injuries in 
humans. The repair of bone fractures is a postnatal regenerative process that recapitulates 
many of the ontological events of embryonic skeletal development [41]. Although fracture 
repair usually restores the damaged skeletal organ to its pre-injury cellular composition, 
structure and biomechanical function, about 10% of fractures will not heal normally [41]. 
A schematic representation of the process occurring after trauma is shown in Figure 3. 
 
 
Figure 3-Bone healing chronological scheme: femur example. In blue are represented the 
major metabolic phases and in brown the biological ones. Taken from Einhorn, T. A., & 
Gerstenfeld, L. C. (2015) [43] 
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The bone healing phenomenon endows several stadia that occur in a sequential manner: 
inflammation, soft callus formation, hard callus formation and bone remodeling [41]. The 
different bone healing stadia are reviewed in the following topics: 
• The inflammatory phase, which is characterized by the proliferation and 
migration of mesenchymal progenitor cells to the fracture site [42]. At this stage, blood 
also enters the defect, forming a hematoma [42]. There, several pro-inflammatory 
cytokines and growth factors (including tumor necrosis factor-alpha - TNF-α, interleukin-1 
(IL-1), IL-6, IL-11 and IL-18) are expressed in a temporally and spatially controlled 
manner [43]. These signals recruit inflammatory cells and promote angiogenesis [43]. At 
this stage, platelets are recruited and activated in the defect site and produce transforming 
growth factor-β1 (TGF-β1) and platelet derived growth factor (PDGF) [43]. 
Simultaneously, recruited osteoprogenitor cells express BMPs which, in coordination with 
other factors, promote the recruitment and osteodifferentiation of MSCs [44,45].  
• The soft callus formation. After the formation of a blood hematoma, blood cells, 
fibroblasts and immune cells are recruited to the injury site, forming the granulation tissue 
[43]. Bone is formed in the peripheric regions of the fractures sites via intramembranous 
ossification (Reviewed in Section 3) after 7 to 10 days after injury [46]. The inner parts of 
the fracture, which are mechanically less stable [47], are replaced by fibrovascular tissue 
(mainly composed of fibroblast cells). Cartilage is formed and, thus, a differentiation of the 
progenitor cells into chondrocytes takes place. These cells then proliferate until complete 
differentiation into a mature hypertrophic phenotype [43]. At this stage, TGF-β2 and -β3, 
as well as BMPs, mediate cell differentiation and proliferation at the injury site [48]. Upon 
the completion of this process, the soft callus if formed [43]. By the process of 
endochondral ossification (reviewed in Section 3), the soft callus is transformed in the 
hard callus, with a mineralized matrix, and the formation of primary bones and/or woven 
bone is started [43]. 
• The formed primary bone is gradually replaced by secondary (lamellar) bone, in the 
bone remodeling process [49]. At this stage, osteocytes undergo apoptosis in a 
reestablishment of the normal bone physiology. This stage can occur throughout several 
years [50].  
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Several immune system cells take part of the bone healing process. Macrophages are 
known to be highly influential of these processes; some studies point to their presence in 
the healing cascade [51-53], and their absence in the healing place can lead to a complete 
depletion on the regeneration of the tissue [54]. In bone healing, an optimal balance 
between M1 macrophages (with the role of initiating the inflammatory response [55] and 
secreting pro-inflammatory cytokines [56]) and M2 macrophages (responsible for tissue 
remodeling, with a phenotype induced by IL-4 and -13, and secreting IL-10 [56]) functions 
must be met, so an adequate regeneration of the tissue is achieved. These two macrophages 
types work together to start and finish the immune response, in an interlocked chain of 
events [57]. The initiation of the inflammatory response is carried out by the M1 
macrophages, which are thought to be gradually substituted by pro-heling M2 
macrophages [58]. An unbalance corresponding to a long M1 macrophages permanence at 
the defect site may lead excessive inflammation, which may compromise fracture healing 
[59]. 
A study by Schlundt et al. [60] showed that, although the reduction of macrophages did not 
appear to have any effect on bone regeneration in initial regeneration steps, the formation 
of the hard callus was delayed, and thus affecting endochondral ossification efficiency. The 
authors focused on determining in which specific time did M1 and M2 macrophages start 
to act. Since one of the most promising results they observed was the great presence of M2 
on the ossification process, they induced this macrophage type (using IL-4 and 13 
cytokines) and verified that bone formation was greatly enhanced.  
Besides macrophages, other cell types are also present in the fracture location, which 
include monocytes, neutrophils and NK cells [61]. These cells produce cytokines that are 
responsible for the recruitment and activation of other cells with differentiation and 
proliferation potential to regenerate the tissue (e.g.: osteoprogenitor MSCs) [59]. When 
osteoprogenitor cells are recruited to the fracture place, their osteodifferentiation is 
partially induced immune cells present at the injury site [62]. 
Other immune cells known to participate in the healing process are T-lymphocytes: they 
act by inhibiting the healing process through the action of cytokines (IFN-γ (interferon 
gama) and TNF-α) [63-67]. Conversely, MSCs have been reported to affect the immune 
response in a plethora of ways, by suppressing or inhibiting it. This response is coordinated 
by the cellular microenvironment and the MSCs-to-T-lymphocytes ratio, with a high ratio 
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inhibiting the immune response, and a low ratio inducing it [66-69]. Nonetheless, the 
MSCs/T-cells interactions still require further studies, so their crosstalk is completely 
understood. The known interactions between MSCs and immune cells present at the period 
of bone fracture healing are depicted in Figure 4. The interactions between immune cells 
and bone cells are reviewed in Section 5. 
 
Figure 4- Scheme of the several mechanisms of MSCs modulation on immune cells. A) 
direct cell-cell contact, b) soluble factor interactions. Taken from Kovach T. K., et al. 
(2015) [70]. 
5. The adult bone cellular niche 
5.1. Bone primary stem cell niche 
The bone tissue comprises two primary niches: the osteoblastic and the vascular niche [4].  
Two stem cells types - hematopoietic (HSCs) and mesenchymal (MSCs) – reside in the 
bone cavity, which is filled with bone marrow and blood vessels [71]. HSCs, which are 
surrounded by stromal cells in the bone marrow, are responsible for the formation of the 
immune and blood system, as well as osteoclasts [72]. MSCs also reside in the bone 
marrow and intervene in the formation of the mesenchymal lineage cells, which include 
osteoblasts, adipocytes, chondrocytes, fibroblast and other stromal cells [72]. Together, 
both stem cell types maintain the normal bone homeostasis and cellular generation [72]. 
Unlike what was thought until recent years, HSCs are not located on the inner surface of 
the bone [73]. Instead, HSCs were recently described to be on the perivascular niche where 
they are regulated by growth factors, chemokines and cytokines (ex: stem cell factor, 
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chemokine stromal cell-derived factor 1 (CXCL-12) and angiopoientin-I), through CXCL-
12-abundant reticular cells, endothelial cells and MSCs [74,73]. 
MSCs, characterized by the expression of PDGFRα, CD51, nestin, CD139, interferon-
induced GTP-binding protein MX1 (Mx1), leptin recptor (Lepr) and Prx, give rise to 
osteoprogenitor cells that form the osteoblastic niche. Thereafter, the factors referred 
previously are released to promote a correct HSC maintenance (reviewed by Yin, T., & Li, 
L. (1936) [76]). The maintenance of a functional microenvironment in the bone niche is 
dependent on the precise level of the hierarchical linages of the HSCs and MSCs, so that 
osteoblastogenesis and hematopoiesis can maintain a correct balance of osteoblast and 
osteoclast production. Importantly, only a subset of N-cadherin positive osteoblasts 
interacts with HSCs, since they help these cells in anchoring to the osteoblastic niche [77]. 
Cell signaling inside the bone niche, for example between osteoblasts and B lymphocyte 
precursors, is well known to determine features of the immune system [74]. Since in this 
Review immunogenesis will not be discussed, the interactions occurring in the bone niche 
will be described regarding the correct function of the bone tissue itself (see Section 5). 
However, it must be emphasized that the bone niche must maintain not only a proper 
functioning bone development, but also a continuous exportation of immune cells and 
tissue progenitor cells to the peripheral immune system, thus sustaining tissue repair and 
regeneration [78] (Figure 5). 
 
Figure 5 – Scheme of the bone cell differentiation process. The MSCs start by differentiate 
into prosteoblasts and then give rise to the osteoblasts, which then mature into osteocytes. 
Taken from Walsh, M. C. et al. (2016) [79]. 
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5.2.  Bone cells (resident) 
5.2.1. Osteoblasts 
Osteoblasts synthetize new bone matrix [1]. Different sub-populations of osteoblasts have 
shown to respond differently to several signals (mechanical, hormonal and from cytokines) 
[1]. Under physiological conditions, MSCs must undergo the Wnt/β-catenin pathway to 
differentiate into the osteoblastic phenotype. Osteoblasts have a cuboidal morphology 
while proliferating on the bone matrix surfaces, unlike their precursors cells 
(preosteoblasts), which have a spindle shape [1]. Mature osteoblasts secrete bone ECM 
proteins, such as collagen type I [80]. Typical gene indicators of osteoblast expression are 
Runx2, distal-less homeobox 5 (Dlx5), osterix (Osx) and ColIA1 [81, 82]. 
Osteoblasts can be divided in two types: mesenschymal (MOBL) or surface osteoblasts 
(SOBL) [83]. In the bone matrix, the undifferentiated MSCs start to differentiate into 
MOBL, which secrete collagen all thought the matrix, forming a woven structure, with 
random orientation of the collagen fibrils. After the creation of sufficient woven bone to 
form a platform-like structure, SOBL secrete collagen fibrils in a parallel way onto the 
previously made bone structure, creating the lamellar bone. Once this process finishes, 
osteoblasts are matured into osteocytes surrounded by collagen matrix [84] (Figure 6).  
 
Figure 6 – Schematic representation of the differentiation of pre-osteoblast cells into 
osteoblasts, and into mature osteocytes. Figure taken from Miron, R. J. & Zhang, Y. F. 
(2012) [85]. 
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5.2.2. Osteocytes 
Osteocytes descend from the mesenchymal lineage, as they are differentiated osteoblasts 
(Figure 6) [85]. They compose 90% to 95% of the whole bone cells in adult bone, and may 
live up to decades in their mineralized environment, where they have a dendritic 
configuration. Their function is to support the skeleton and bone metabolism. As 
osteoblasts transition to osteocytesm the expression of alkaline phosphatase decreases, and 
casein kinase II and osteocalcin are elevated [1]. Other expressed markers include 
phosphate-regulating gene with homologies to endopeptidases on the X chromosome 
(PHEX), matrix extracellular phosphoglycoprotein (MEPE), dentin matrix protein 1 
(DMP-1), fibroblast growth factor 23 (FGF-23), sclerostin, and oxygen regulated protein 
(ORP143), thought to protect against hypoxia [1]. These cells, located on the mineralized 
portion of the bone, were considered as “passive placeholders in bone” in the past. 
However, they were proved to have numerous functions, including bone remodeling, 
through the activation of both osteoclasts and osteoblasts, and also in endocrine cell 
functioning. [86]. The interactions between osteocytes and osteoblasts/osteoclasts is 
reviewed in Section 5.3.1. Osteoclasts are also responsible for the excretion of ECM 
proteins such as CD44, galectin 3 and osteocalcin. These proteins have the function to 
promote cell adhesion and the regulation of the mineral exchange in the bone. Osteocytes 
also express Cbfa1 and osterix, which are required for osteoblast differentiation, and are 
followed by alkaline phosphatase and collagen, necessary for the formation of the osteoid: 
the unmineralized collagenous matrix preceding bone [86]. Several soluble molecules 
produced by osteocytes interfere with biomineralization (e.g. PHEX, MEPE and DMP-1) 
[86]. The communication between osteocytes, occurring mainly by gaps composed of 
connexin 43 [87], are required for their survival, maturation and correct activity. The 
diverse roles of osteocytes also endow their phagocytic activity, during osteolysis, since 
they have lysosomes in their constitution. Also, one of the main functions of osteocytes is 
mechanosensing by translating stress factors into biologic signals [86]. The 
mechanotransduction phenomena occurring in bone through the action of osteocytes and 
other bone cells is reviewed in Section 7. 
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5.2.3.  Osteoclasts 
Osteoclasts, generated in the bone marrow from the mononuclear monocyte-macrophage 
precursors (derived from the hematopoietic lineage) [88], are the only cells capable of 
resorbing bone and, consequently, play an essential role in bone remodeling. Two 
cytokines – receptor activator of nuclear factor kappa-β ligand (RANKL) and macrophage 
colony stimulating factor (M-CSF) – drive osteoclasts’ proliferation, differentiation and 
survival [88,89].  Bone resorption occurs in the presence of hydrogen ions (acidification of 
the resorption compartment, dissolving the mineral bone matrix) and cathepsin K (enzyme 
responsible for the digestion of the insoluble fraction of the matrix, manly type I collagen), 
both secreted by osteoclasts.  These cells are bound by the bone matrix through integrins 
(β1 for collagen, laminin and fibronectin, and αvβ3 for osteopontin and bone sialoprotein) 
[88]. Such binding polarizes osteoclasts, creating an actin ring that seals the periphery of 
the ligation of the osteoclasts to the matrix, and a ruffled border in the resorbing surface, 
which leads to the secretion of H+ ions, followed by the exocytosis of enzymes from the 
acidified vesicles [88]. 
 
5.3. Cell-cell interactions in bone 
It is well established that bone cells interact in adult bone to regulate the homeostasis 
process, supporting the balance between bone resorption and formation that allows the 
maintenance of the tissue’s integrity [90]. We review the interactions between the main 
cells constituting the healthy bone – osteoblasts, osteoblasts and osteocytes -, and the 
crosstalk occurring between such cells and the vascular system that irrigates bone. The 
main interactions between immune cells, present in bone fracture sites, with constituent 
bone cells is also reviewed.  
 
5.3.1. Osteocytes – osteoblasts 
Bone formation is regulated by several signaling pathways, from which the Wnt/β-catenin 
pathway is one of the most important [1]. The activation of canonical Wnt signaling in 
early osteoblasts promotes osteoblast differentiation and bone formation [91], with 
opposing effects observed when Wnt signaling is disrupted [92]. Osteocytes secrete Wnt 
antagonists, which include sclerostin and the LRP5/6 inhibitor DKK1 (Dickkopf-related 
protein 1). Both molecules were shown to inhibit osteoblast differentiation and bone 
formation [93-95]. Also, the in vivo loss of secreted frizzled-related protein 1 (SFRP1), 
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which is a competitive antagonist of Wnt ligand, resulted in increased bone mass and 
mineral density, and in vitro enhancing osteoblast proliferation and differentiation into 
osteocytes [96]. With their capacity to interfere in canonical Wnt signaling, therefore 
affecting osteoblasts differentiation, osteocytes show a regulating role in bone formation. 
 
5.3.2. Osteoblasts-osteoclasts 
Signaling between osteoblasts and osteoclasts is crucial for osteoclast maturation [1]. It is 
known that osteoblasts and stromal cells express RANKL, M-CSF, and 
osteoprotegerin (OPG), while early osteoclast precursors express c-Fms (M-CSF 
receptor) and receptor activator of nuclear factor κ B (RANK) (a receptor for RANKL) 
[97]. RANKL (the RANK ligand) and M-CSF stimulate osteoclast differentiation, 
while OPG is an inhibitor of RANKL, and competes with RANKL for RANK [98]. 
Low levels of OPG lead to accelerated osteoclast development, which culminates in 
osteoporosis, in which the bone resorption/formation balance is disrupted, and bone 
resorption exceeds bone growth [99]. In summary, the interactions between osteoblasts 
and osteoclasts are of extreme importance in the regulation of bone resorption and 
formation, and disruptions in this balance may trigger disease scenarios. 
 
5.3.2. Osteocytes – osteoclasts 
Osteocytes – both healthy and apoptotic at microdamage sites – have been reported to 
recruit osteoclasts to the bone remodeling sites [100], and were shown to send bone 
resorption cues to these cells [100-102]. The expression of the RANK ligand (RANKL) 
during the dendritic process associated with osteocytes maturation was associated with the 
osteocyte-led bone resorption [100]. Upon injury, right after damage, pro-apoptotic 
molecules are released by osteocytes; contrarily, anti-apoptotic molecules are expressed 1-
2 mm from the cracks [100, 103]. The promotion of a defective performance of osteocytes 
in mice, through β-catenin deletion, led the increased osteoclasts activity, showing that 
osteocytes are necessary for a correct regulation of osteoclasts activity, and therefore, of 
the bone remodeling process [100]. Another indication of the close osteocyte/osteoclast 
interaction was the formation of osteocytes induced, in vitro and in vivo, by osteoclasts 
apoptotic bodies; the contact with osteoblast-derived apoptotic bodies did not have this 
effect [100,104]. Moreover, the induction of osteocytes formation by exposure to 
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osteoclasts’ apoptotic bodies was not driven by RANKL, as it was shown to be a TNF-α-
dependent process. 
 
5.3.3. Vascular cells – osteoblasts 
Bone-associated blood flow is responsible for the control of oxygen and nutrient 
delivery/exchange in the tissue. Also, bone formation and resorption are coupled with bone 
hemodynamics. During endochondral ossification, the vascularization of hypertrophic 
avascular cartilage is one of the determinant steps for bone elongation. During fracture 
healing, the generation of an efficient new tissue is also dependent on a successful 
vascularization. A tight connection between the growth of blood vessels in bone and the 
osteogenesis process has been reported [105]. Endothelial and osteoblastic cells have a 
molecular crosstalk in which angiogenesis and osteogenesis and synergistically promoted. 
Osteoblasts are known to secrete angiogenic factors, including vascular endothelial growth 
factor (VEGF) [106] and erythropoietin [107], which mediate their cross-talk with 
endothelial cells. Nonetheless, the mechanisms and molecules involved in this process 
have not yet been fully unraveled.  
Recent findings have presented bone vasculature as a unique network, with substantial 
differences from other body vascular systems. Interestingly, vascular growth in bone was 
proved to be obtained by a tissue specific angiogenesis, in which the Notch pathway is 
responsible for the endothelial cell proliferation and the blood vessel growth in post-natal 
long bone. In a study conducted by Ramasamy et al. , the authors verified a deficiency on 
the bone vessel growth and morphology by knocking out the gene responsible for the 
Notch signaling. In turn, this led to reduced osteogenesis, resulting in the irregularity of 
bone structure in mice [108]. Recently, Huang et al. [109] identified chemokine (C-X-C 
motif) ligand 9 (Cxcl9) as a angiostatic factor secreted by osteoblasts in the bone marrow 
environment. Mice with constitutive mTORC1 (an Cxcl9 activator) in osteoblasts 
demonstrated enhanced VEGF secretion; however, this was accompanied by an 
unexpected decrease in the phosphorylation of its receptor (VEGFR2), as well as 
downstream signaling in endothelial cells, and reduced vasculature formation in bone.  
The structure of bone vasculature has also shown to be unique by Kasumbe et al., who 
identified a new capillary subtype in the murine skeletal system, presenting distinct 
molecular, morphological and functional properties. These vessels were shown to be 
crucial for the correct bone development and maintenance, since they generate a distinct 
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molecular and metabolic microenvironment, linking angiogenesis and osteogenesis, and 
lastly maintaining perivascular osteoprogenitors [110]. 
 
5.3.4. Immune cells interactions with bone cells 
Despite not being found in bone tissue in healthy conditions (with the exception of 
“osteomacs”), immune cells residing in the bone marrow are in a close anatomic location 
with bone. The crosstalk between bone cells and immune system cells has often being 
overlooked, and usually focus on the role of such cells in disease [111]. We here report 
some of the studied cell crosstalk facts involving bone cells, and bone-related or bone-
constituent (osteomacs) immune cells, related to the regulation of bone’s normal 
physiology.  
The reduction of bone-related immune cells of B- and T- lymphocytes in mice have led to 
osteoporotic scenario [112]. Moreover, it is known that mature B-cells produce more than 
half of bone marrow-derived OPG, contributing to osteoclastogenesis restriction [112]. It is 
also thought that T-lymphocytes may interact with B-cells to enhance OPG production 
[113]. Hematopoietic stem cells-derived megakaryocytes, known to produce platelets, were 
shown to enhance the in vitro osteoblast proliferation and differentiation through the 
expression of RANKL, OPG and some unknown anti-osteoclastic factors [114]. 
Nonetheless, the role of megakaryocytes is still unclear in bone physiology.  
Osteomacs are probably the most studied immune system cells in bone tissue. They reside 
on the endosteal and periosteal surfaces, and compose 10 to 15% of most tissues [115]. In 
vivo, osteomacs form a shell over mature matrix-producing osteoblasts at sites of bone 
modeling. Depletion of macrophages in vivo results in complete loss of endosteal 
osteomacs and their associated osteoblasts, suggesting that osteomacs are needed to 
maintain mature osteoblasts in the bone structure [113,116].  
5.4. Cell-cell contact in bone– the role of cadherins, connexins and pannexins 
Cells can communicate by two processes, involving indirect and direct contact. Most 
interactions occurring during bone formation, development and remodeling have been 
shown to occur via cellular direct contact. Cadherins are the main proteins responsible for 
cell-cell adhesion [117]. These proteins are glycoproteins located at the cell membrane, 
which promote cell-cell adhesion by a calcium-mediated mechanism. Cadherins (molecular 
weight around 120 kDa) are constituted by two domains: the extracellular and the 
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transmembrane domain. The calcium-binding site (five repeats; responsible for the ability 
of cells to bind the same cadherin) is located in the extracellular domain. Cadherins can be 
classified in the following way: type I and type II. In these two types, cadherins can be 
divided even more: type I: N-, E, M- and R-; type II: 5 to 12 [117]. Cadherins have a 
cytoplasmic C-terminal tail that is responsible for the stabilization of the adhesion. This 
structure is organized by the binding of cadherin to β-catenin and plakoglobin, which 
connect cadherins to the actin cytoskeleton, via N-catenin, actinin, ZO-1 and vinculin. This 
binding is a dynamic process. Adherent junctions are the junctional structures between two 
adjoining cells that allow communication and adhesion between cells [117].  
In bone, there are three major cadherins: E-cadherin, N-cadherin and cadherin-11 [118-
121]. Cell-cell adhesion mediated by cadherins is essential for the function of bone-
forming cells during osteogenesis. The inhibition of these cadherins was shown to inhibit 
osteoblasts differentiation [122]. During osteoblast differentiation, cadherin-2 is 
downregulated over the process, and cadherin-11 becomes the main cadherin for osteoblast 
functions. For successful osteogenesis, cell-cell contact amongst cells of the ostoblastic 
lineage and the osteoclasts precursors is necessary. This interaction is mediated by RANK 
(receptor) and RANKL (ligand). RANK is present in osteoclasts precursors, while RANKL 
is present in the membrane of osteoblastic cells [1].  
Connexins are proteins involved in cell-cell contact, allowing the rapid dissemination of 
molecules (smaller than 1 kDa) and ions by diffusion among cells. They link cells through 
gap junction channels, that facilitate electrical and chemical coupling [122]. The most 
widely reported connexin in bone - expressed by osteocytes, osteoblasts and osteoclasts - is 
Cx43; those cells were also shown to express Cx37 [123], and osteoblasts also express 
Cx45 and Cx46. When osteochondroprogenitors, as well as committed osteoblast 
progenitors, are deleted from Cx43, there is a decrease in bone mass and density [123]. 
Interestingly, the deletion of this connexin from mature osteoblasts and osteocytes did not 
lead to any effect on bone mineral density or bone length [123]. This suggests that Cx43 is 
essential for osteochondral progenitors, but not in committed osteoblasts [123]. Cx37 has 
recently been proved to regulate bone mass [124]. Deletion of this connexin led to increase 
in bone mass; however, this effect was shown to be gender dependent, with males being 
more affected than females [124]. The higher bone mass observed in individuals with 
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depleted Cx37 is related with a decrease in osteoclast differentiation, driving impaired 
bone resorption [125]. 
Pannexins are proteins with a very similar structural topology to connexins. However, their 
sequence is not homologous with connexis, and they only function as an unpaired channel 
[125-127]. One of the genes encoding pannexins - Panx1 - is present in murine osteoblastic 
cells [128], whereas Panx3 is expressed in various osteoblastic cell lines and primary 
calvaria cells and in hypertrophic chondrocytes [129-132]. Although some studies have 
studied the role of pannexins in vitro in osteoblast differentiation, in vivo studies are still 
missing [125]. 
 
5.5. Cells-extracellular matrix (ECM) interactions in bone 
5.5.1. Cell signaling and adhesion   
The ECM is a complex network comprising proteins (soluble and insoluble), growth 
factors and polysaccharides. It provides physical structure and a biochemical context to the 
cellular microenvironment [133]. In body tissues, the communication amongst cells and 
the surrounding ECM is mainly made through three types of proteins: integrins, selectins 
and immunoglobulin [134]. This adhesion contributes to cell biological process as: 
immune response, metastases, inflammatory process, division and death of cells, tumor 
progression and cell polarity. Figure 7 shows a schematic of the various interactions that 
occur in the ECM.  
 
Figure 7 – Schematic representation of cell-ECM interactions. Figure taken from Wade, R. 
J., & Burdick, J. A. (2012)[135].  
23 
 
5.5.3. The adult bone extracellular matrix: the role of proteins and proteoglycans 
The bone matrix is mainly composed of collagen (85-90%) and other types of proteins. 
The ECM has two mechanisms by which it affects cellular behavior: (i) by the direct 
interaction with the cells, and (ii) by harboring growth factors for cell proliferation and 
differentiation [136]. 
The connection between cells and ECM proteins - case (i) - is made through proteins 
existing on cell surface, integrins, which regulate not only the cell-to-physical matrix 
adhesion, but are also responsible for some intracellular signals. These proteins recognize 
specific peptide sequences and bind to specific peptide domains by the presence of two 
distinct subunits: α and β. The binding of the ligand to this intramembranous protein is 
dependent on the association of these two subunits, making it possible for only one integrin 
to recognize and connect to specific types of ECM proteins [137,138]. 
Huang et al. [139] studied the effects of mechanical factors (i.e. ECM stiffness) and 
presence of ECM insoluble proteins, in a combined effect, to assess their effect on the 
osteogenic differentiation of MSCs, cultured as two-dimensional monolayers, in basal 
medium. The tested ECM cell-binding proteins - type I collagen, fibronectin, vitronectin 
and laminin - induced the in vitro osteogenic differentiation of MSCs, implying that the 
right ECM composition is enough to induce the MSCs osteogenic differentiation. This 
study also showed that, although type I collagen is the main protein in bone ECM, no 
difference was observed in its capacity to induce more osteogenic differentiation than the 
other tested proteins. In fact, fibronectin showed more ability to drive osteogenic 
differentiation, followed by laminin, type I collagen, and vitronectin. The authors also 
verified that mechanical stretching of the cells improved differentiation. Another in vitro 
study by Mathews et al. [140] showed that type I collagen and laminin were the most 
successful ECM proteins in inducing the proliferation and adhesion of MSCs, and a high 
percentage of MSCs differentiation occurred by contact with fibronectin, vitronectin and 
collagen type I. Combinations of adhesive ECM proteins – fibronectin, laminin, 
osteocalcin – mixed with methacrylate gelatin hydrogels were suggested by Dolatshahi-
Pirouz et al. [141] as a way to study the combinatorial role of ECM proteins and soluble 
factors in bone marrow MSCs, using a high-throughput strategy. Mixtures of proteins in 
the presence of bone-inducing cytokines led to higher osteogenic differentiation of MSCs. 
Gothard et al. [142] studied the in vivo effect of adding growth factors and osteoinducing 
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soluble molecules to an alginate/demineralized bone ECM hydrogel. All formulations, 
even the ones excluding growth factors or soluble factors, induced bone formation in rats. 
The authors hypothesized that this behavior may be related to reminiscent amounts of 
cytokines in the demineralized bone ECM used to synthetize the hydrogels. The UV-
irradiation of the hydrogels, leading to the denaturation and fragmentation of the cytokines 
suggested that, indeed, this could be the explanation for the observed general bone 
formation. 
The cytokine-matrix adhesion in bone ECM is accomplished by proteoglycans: a family of 
biomolecules composed of a core protein and a covalently attached sulfated 
glycosaminoglycan (GAG) [143]. GAGs are linear polymeric disaccharides, comprising 
hexosamine and hexuronic acid (except for keratan sulfate). Together with collagens, 
proteoglycans are the major constituents of bone organic ECM. The proteoglycans found 
in bone can be mostly divided in two families: (i) the small leucine-rich proteoglycans 
(SLRPs) and (ii) heparan sulfate proteoglycans (HSPGs). SLRPs are the most abundant 
proteoglycans in bone, and include decorin, biglycan, fibromodulin, lumican, osteoadherin 
and PG-Lb [141]. They have been associated with all phases of bone formation, and 
mediate signaling pathways regulating the osteogenic program, including the activities of 
TGF, BMPs and Wnt, which influence both the number of available osteogenic precursors 
and their subsequent development, differentiation, and function [143]. HSPGs are thought 
to be produced by osteoblasts and osteoclasts, and play an important role in cell–cell 
interactions between fibroblast-like cells and osteoclast-lineage cells by reserving heparin-
binding growth factors and/or heparin-binding adhesion molecules, such as fibronectin 
[143]. HSPGs are known to regulate the availability and the biological activity of TGF-βs 
and FGFs, two major growth factor families involved in the regulation of bone biology. 
The following table (Table 1) is a compilation of ECM proteins described as intervenient  
on bone modeling/remodeling.  
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Table 1- A list with examples of ECM proteins responsible for the bone formation and regeneration 
Protein Physiological localization  Biological function Ligation site 
Ameloblastin 
• Pulp [144] 
• Enamel [144] 
• Hertwig’s epitelial root sheath 
[144] 
• Periodontal ligament [144] 
• Calvarial development [144] 
 
• Regulation of crystal growth [144] 
• Cell signaling [145] 
• Dentin and bone repair induction [145] 
• Bone healing stimulation in vivo [145] 
•  Enhancement of proliferation and differentiation of stem cells, 
osteoblasts and osteoclast precursor cells (in vitro) [144] 
• Fibronectin interaction site [144] 
• Heparin-binding domains [144] 
• CD63-interaction domains [146] 
• Calcium binding sites [144] 
 
 
Fibronectin 
• Conective tissues (including 
bone) [147] 
• Bodly fluids [147]  
• Cells adhesion, growth, migration, and differentiation 
[148,149] 
• Integrin (α4β1,α5β1,αVβ3,αIIbβ3,αVβ6,αVβ5) 
[150] 
• Extracellular matrix components (collagen,  
fibrin and heparan sulfate proteoglycans) [150] 
Laminin 
• Basal lamina (bone) [151] 
• Endothelial [151]  
• Cell survival, proliferation, differentiation and specialized 
functions [152] 
•  Although laminin is not effective at promoting osteoblast 
differentiation, it had some proliferative and adhesive activity 
on stem cells [140] 
• Integrin (αVβ3,α2β1, α1β1,α3β1) [150] 
Vitronectin 
• Bone [153] • Adhesion of endothelial cells, fibroblasts and bone-derived 
cells [149,154]  
• integrin (αVβ3,αVβ5) [150] [154] 
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• Liver [153] 
• Brain [153] 
• Fat [153] 
• Heart [153] 
• Skeletal muscle [153] 
• Lung [153] 
• Uterus [153] 
• Testis [153] 
• Thymus [153] 
• Regulation of the fibrinolytic, complement and coagulation 
systems [155]   
 
Collagen type I 
• Flesh and connective tissues of 
animals (cornea, cartilage, bone, 
blood vessels, gut, and 
intervertebral discs) [156] 
• Regulation of bone cell phenotypes [156,157] • Integrin (α2β1) [150] 
Collagen type IV 
• Bone- trace amounts [151] • Collagen fibril diameter regulation [149] • Integrin (α2β1) [150] 
• CD44 [150] 
Collagen type X 
• Calcilfied cartilage [158]  • Support the bone that is forming [159] 
• Aid in the removal of type II collagen fibrils [159] 
• Mineralization [159] 
• Vascular invasion of the cartilage matrix [159] 
• Runx 2 [160]  
• Ca2+ [161] 
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Osteonectin 
(SPARC) 
• Bone [162] 
• Pericellular matrix surrounding 
osteoblasts and osteocytes [162] 
 
• Osteoblasts differentiation and survival [163] 
• Adipogenesis inhibition [163] 
• Regulates collagen fibril diameter [149, 164] 
• Cell spreading [162,165]  
• Collagen fibrillogenesis [166]  
• Ca2+ and hydroxyapatite binding [162] 
 
• Hydroxyapatite [162] 
• Ca2+ [162,165] 
• Collagens [165] 
• PDGF [165] 
• TGFβ1 [165] 
• VEGF [165] 
• MMP2 [165] 
• bFGF [165] 
• IGF [165] 
Osteocalcin 
• Extracellular matrix of areas of 
newly formed bone, i.e. in the 
subperiosteal region [162] 
• Subchondral region [162] 
• Osteoid tissue (surface of the 
trabecular bone) [162] 
• Matrix of the bone marrow cells 
[162] 
• Bone turnover [162] 
• Regulates osteoclasts [149] 
• Inhibits mineralization [149] 
• Marsk osteoblast differentiation [166] 
• Calcium binding [162] 
 
• Ca2+ [162] 
• Collagen [162] 
• Hydroxyapatite [162] 
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• Kidney [162] 
• Salivary and renal tube 
epithelium [162] 
Biglycan 
• Bone [162,167] 
• Articular Cartilage [162] 
• Endothelial cells of dermal 
blood vessels [162] 
• Prickle cell layer [162] 
 
• Cell spreading [162] 
• Calcium and hydroxyapatite binding [162] 
• Decrease the availability of active TGF-β [149¸166] 
• Collagen fibrillogenesis promotion [149,166] 
• Bone formation induction [168] 
• Cell-cell and/or cell-protein interactions [162] 
• Collagen [149] 
• TGF-β [162] 
• BMP2 [168] 
• Ca2+ [162] 
• Hydroxyapatite [162] 
Bone sialoprotein 
(BSP) 
• Bone [169] • Mineralization regulation [149, 165, 166]  
• Osteoblast and osteoclasts differentiation, adhesion and 
function [170,171] 
• Angiogenesis promotion [172] 
• Mediates cell attachement [162] 
• Integrins [165] 
• Collagen [165] 
• Ca2+ [165] 
• Hydroxyapatite [165] 
• MMP2 [165] 
• Complement factor H [165] 
Osteopontin 
(Secreted 
phosphoprotein 1; 
OPN)  
• Bone [162] 
• Kidney [162] 
• Endometrial glans of a 
• Cell attachment [162] 
• Hydroxyapatite binding [165] 
• Mineralization and remodeling inhibition [149] 
• Integrins [165] 
• CD44 [165] 
• Fibronectin [165] 
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nonpregnant secretory-phase 
uterus [162] 
• Osteoblast and osteoclasts differentiation, adhesion and 
function [170, 173, 174] 
• Hydroxyapatite nucleation regulation [175] 
• Inhibits mineralization and remodeling [175] 
• Promotes bone resorption [175] 
• Hydroxyapatite [165] 
• Ca2+ [165] 
• Collagens [165] 
• MMP3 [165] 
•  Complement factor H [165] 
• EGF [165] 
• PTH [165] 
Decorin  
 
• Bone [162] 
• Nonarticular resting cartilage 
[162] 
• Dermal collagenous matrix 
[162] 
  
• Collagen binding [162] 
• Fibril formation regulation [162] 
• Decreases the availability of active TGF-β [166] 
• Collagen fibrillogenesis promotion [166] 
• Regulate collagen fibril diameter [149] 
• TGF-β [149] 
• Collagen [162] 
Thrombospondin (
Type I and Type 
II) 
 
• Endomysium and perimysium 
[176] 
• Basement membranes of the 
muscle capillaries [176] 
• Muscular and tendinous parts of 
the myotendinous junction [176] 
• Bone marrow [176] 
• Cell attachment [149,162] 
• Osteoclast function regulation (type I) [177] 
• Inflammation regulation (type I) [166] 
• TGF-β activation (type I) [167] 
• TGF-β sequestration and collagen fibrilogenesis (type II) 
[167] 
• Collagens [165] 
• Heparan sulfated proteoglycans (type I) [165] 
• Fibronogen (type I) [165] 
• Laminin (type I) [165] 
• Ca2+ (type I) [165] 
• Fibronectin (type I) [165] 
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• Articular cartilage [175] 
 
 
• MSCs proliferation inhibition (type II) [178] 
• Osteoblast differentiation promotion (type II) [178] 
• Adipogenesis inhibition (type II) [178] 
 
• Integrins [165] 
• HSPG [165] 
• CS47 [165] 
• CD36 [165] 
• LRP [165] 
• Syndecan (type I) [165] 
• Thy-1 (type I) [165] 
• Calreticulin (type I) [165] 
• TGF-β (type I) [165] 
• Cathepsin (type I) [165] 
• Elastase (type I) [165] 
• PDGF [165] 
• bFGF (type I) [165] 
• MMP2 [165] 
• IGF-1 [165] 
• IGF-BP (type I) [165] 
• Chondroitin sulfate (type II) [165] 
• Proteoglycans (type II) [165] 
Tenascin C 
• Muscle cell endings of the 
myotendinous junction [176] 
• Osteoblast differentiation [179] 
• Fibronectin desposition [164] 
• Fibronectin [165] 
• Integrins [165] 
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• Tendon cells [176] 
• Surfaces of the tendinous 
collagen fibers [176] 
• Pericellular space 
surrounding some osteocytes 
[179] 
• Articular cartilage [179] 
 
• Contactin/F11 [165] 
• Annexin II [165] 
• Heparan sulfated proteoglycan [165] 
Periostin 
• Bone periosteum [180] 
• Periodontal ligament and 
tendons [180] 
• Cortical bone thickness control [180] 
• Negative regulator of matrix mineralization [180] 
• Crosslinking of collagen fibrils [180] 
•  ECM organization (especially fibronectin and tenascin C) 
[166] 
• SOST regulation [166] 
• Collagen type-I [180] 
• Fibronectin [166] 
• Tenascin-C [166] 
Dentin matrix 
acidic 
phosphoprotein 1 
(DMP1) 
• Bone and dentin [180] • Target molecule for Runx2 [181] 
• Calcium binding [182,183] 
• Initiation of nucleation of crystalline hydroxyapatite 
[182,183] 
• Intra and extracellular signaling molecule [184] 
• Robust osteocyte marker [166] 
• Regulates phosphate metabolism [166] 
• Ca2+ [182,183] 
• DSPP promoter [185;186] 
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• Involved in osteocyte function [166] 
Collagen type III 
• Bone-trace amounts [185] 
• Blood vessels [187] 
• Skin [187] 
• Lung [187] 
• Promotion of bone formation [166] 
• Regulate collagen fibril diameter [149] 
• integrins α1β1 and α2β1 [188] 
• vWF [189] 
 
 
Versican 
• Woven bone matrix [190] • Defines the space destined to become bone [149] • Glycosaminoglycan hyaluronan [190] 
 
TGFβ receptor II 
interacting protein 
1 (TRIP 1) 
• Bone [191] 
 
 
 
 
 
 
 
• Signal transduction, vesicular trafficking and cell cycle 
regulation [191] 
• Influences TGF-β [191] 
• Signaling by acting as a negative regulator and inhibiting 
positive regulation of TGF-β target genes [192] 
• Osteoblast proliferation and differentiation [192] 
• Cytoplasmic domain of TGFβR2 [192] 
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6. Bone mechanobiology:  
6.1. Frost’s “mechanostat” theory: the role of compressive and tensile forces 
Mechanical and physical signals that occur through walking, running and other types of 
movements have a crucial role in the induction of osteogenesis, as well as in the 
maintenance of healthy bone [193]. The “Mechanostat Theory”, suggested by Harold Frost 
in the 1890’s [194], correlates bone growth and loss with local elastic deformation (in the 
form of compression and elongation), which occurs in a life-long regime, due to peak 
forces exerted by surrounding muscles [195]. The control loop of bone elastic deformation 
is categorized in four types - disuse, adapted state, overload and fracture -, correlated with 
distinct deformation values, in which a 1000 µstrains equal 0.1% of the bone length [196]. 
The ideal frequency, intensity, and timing of loading to promote healthy bone mass growth 
are well reported for the in vivo scenario [197-199]. A current challenge for the 
recapitulation of the native bone niche is the optimization of such mechanical stimulation 
for in vitro settings.   
 
6.1.1. The correlation of the “Mechanostat Theory” with bone biochemical signaling  
Interesting observations have been reported during the last years, which correlate the 
“Mechanostat Theory” with biochemical signalling occurring during bone homeostasis. 
Tyrovola & Odont [200] reviewed several studies, in which compressive/tensile 
deformations were applied to bone and periodontal ligament tissues, and established a 
correlation between the observed behavior and the OPG/RANKL/RANK system. An 
example that shows the correlation of the “Mechanostat Theory” and the 
OPG/RANKL/RANK bone remodeling system is the one occurring in the 
tooth/periodontal ligament interface. The compression of tooth, during orthodontic 
movement, led to the increase of RANKL concentration [201,199], promoting osteoclast 
formation. The tensile stretching applied to the periodontal ligament promoted the increase 
of osteoblasts OPG concentration in a magnitude-dependent manner [203], while inducing 
a simultaneous RANKL concentration decrease. The relative concentrations of OPG and 
RANKL on both tensioned and compressed sides of tooth regulate local bone modeling, 
remodeling and root resorption.  
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6.2. Other forces affecting bone behavior: focus on flow-induced shear stress  
Other physical and mechanical factors that influence bone health are the drag force and 
shear stress. Drag force is the sum of all the forces that oppose the flow of the blood [204]. 
Shear stress occurs in the bone, on the unmineralized matrix around the osteocytes, which 
forms canals by which the interstitial fluid passes, creating a force along the surface, on a 
parallel fashion [205]. A consequence of bone deformation is the generation of interstitial 
flow on osteocytes, creating a drag phenomenon on the fibers that connect the cells [206-
210]. Weinbaum et al. [211] suggested a mathematical model to explain how bone cells 
detect mechanical loading, and how flow behaves through the pericellular matrix 
surrounding an osteocyte process in its canaliculus. Despite the small deformations 
predicted by the model, and the small dimensions of the pericellular annulus (typically 
0.1 μm), the fluid flow shear stress on the membranes of the osteocyte processes was 
roughly the same as for the vascular endothelium in capillaries. Still little is known about 
the role of perfusion shear stress and interstitial flow in bone biology [212,213]. However, 
it is known that osteocytes are the main mechanosensing cells in bone and that, upon 
exposure to fluid flow, they stimulate osteoblasts, thus producing more bone tissue and 
prostaglandins, which are responsible for the activity of osteoblasts and osteoclasts [100]. 
Early studies focused on unravelling the effect of hydrostatic pressure and substrate 
stretching on osteocytes behaviour [214]. However, flow-induced shear stress has shown to 
affect osteocytes in a more relevant manner, as compared to osteoblasts [215]. A long list 
of biological phenomena, that has been increasing in the last years, has shown that 
osteocytes respond to shear stress by releasing nitric oxide (NO), adenosine triphosphate 
(ATP) and prostaglandinds. Moreover, gap junctions and hemichannels are open in such 
scenario, and several signalling pathways (e.g. Wnt/β-catenin, protein kinase A (PKA)) are 
initiated after shear stress induction. The mechanisms for load sensing in osteocytes are 
thought to depend on the dendritic process, or bending of cilia [100]. Glycocalyces on the 
surfaces of dendritic processes have been shown to be related with osteocytes 
mechanosensing; however, on the cell body, different mechanosensing mechanism are 
known to be active [100].  The TGF-β family - which includes BMPs, activins, and growth 
differentiation factors (GDFs) - has been suggested as one of the most important mediators 
of cellular response to physical cues via a feedback loop mechanism, reviewed by Wu et 
al. [216].  
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7. Tissue engineering techniques in bone strategies for bone regeneration 
7.1.  Analysis of the clinical needs in the regenerative medicine of bone 
The complexity inherent to bone’s physiology dictates the difficult regeneration of bone 
tissue after a critical size fracture. While bone tissue trauma normally heals by itself, the 
so-called “critical” defects, with average diameter of 2 cm or higher, do not show this 
ability [217]. Critical size defects often derive from tumor ablation, serious injury and 
orthopedic diseases. [218,219]. Considering physically-caused injuries, the bone healing 
repair failure percentage can go from 10 to 50% (data including a range of fractures from 
standard injury to open tibial defects) [220]. As described previously on Section 1, the 
biology of bone and fractures sites is highly complex and dynamic. Although many studies 
shed light into the biology of both bone healthy regulation and healing, the complete 
understanding of the myriad of players (including immune system, external physical 
factors, vasculature and osteogenic lineage cells) is yet to be fully understood. However, 
the failure of bone healing will ultimately culminate in the suppression of the blood supply 
to the tissue, which will result in the non-union of the bone (due to schemia, osteonecrosis 
and bone loss) [221].  
Efforts to repair bone defects, excluding the ones that target bone regeneration, can be 
divided in two main segments: (i) implantation of bone grafts (of autologous or allogenic 
origins) or (ii) development of synthetic bone substitution grafts [222]. However, these two 
therapeutic approaches show limitations. Autologous bone grafts, although commonly 
applied in clinics and known to foster bone repair, can inflict morbidity of the donor’s 
extraction site [223]. Allogenic bone grafts, coming from a different donor, can be rejected 
due to immune response, Moreover, the implantation of allografts requires a complex 
implantation technique that involves the achievement of constant vascular supply to the 
site, as well as a maintenance of an adequate mechanical environment to promote vessels 
formation [224]. Permanent substitution grafts can have some unwanted side effects, which 
may affect bone healing negatively. These include bone resorption, poor integration and an 
adverse reaction (eg: allergenic) to the material [222]. A list of current strategies based on 
synthetic grafts for bone healing is reviewed in references [225,226].  
The listed problems associated with the current bone repair approaches show that there is a 
dire need for new and more efficient strategies. Unlike the previously mentioned 
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techniques targeting bone repair, tissue engineering seeks a complete regeneration of the 
damaged tissue. To achieve that, four main pillars may be used separately or combined to 
design strategies that promote bone regeneration: (i) biomaterials, (ii) biomolecules, (iii) 
cells and (iv) externally-applied stimuli. 
In the following sub-sections, brief explanations of the concepts behind the use of each 
tissue engineering player will be provided. Representative studies in each field, as well as 
combined studies will be presented. Although bone regeneration studies that use 
unifactorial approaches are highly relevant to elucidate the role of single variables on bone 
cells, they do not consider the high complexity of the bone’s microenvironment. Here, we 
review some studies that use multifactorial and, in some cases, biomimetic strategies to 
promote bone regeneration within the tissue engineering scope. 
7.1.1. Biomaterials for bone regeneration 
The re-creation of the bone original tissue requires a structure that mimics the tissue native 
microenvironment, so cells can attach and proliferate [227].  Biomaterials are used in 
tissue engineering strategies as analogous of the bone ECM, which structure is reviewed in 
Section 6.  Materials suggested so far for the construction of biodegradable biomaterials 
for tissue regeneration are mainly composed of ceramics, glasses, polymers or composites 
thereof [228]. Polymeric biomaterials will be described in more detail. Detailed reviews on 
bioceramics and bioglasses can be found in [229,230]. Polymeric biomaterials may be of 
two different origins:  synthetic or natural [231]. Examples of commonly applied synthetic 
polymers used in biomaterials composition include poly(ethylene glycol) (PEG) [232], 
poly(lactic acid) (PLA) [233], poly (L-lactide-co-glycolide) (PLGA) [234] and 
polyglycolic acid (PGA) [235]. Despite their lack of cell-interacting domains, synthetic 
materials are amenable to be chemically tailored using with precision. Natural origin 
materials used for tissue engineering include polyssacharides, proteins and 
polyhydroxyalkanoates [236]. Examples of such widely used proteins for tissue 
engineering include. collagen [237], its denaturated analogue gelatin [238] and silk [239]. 
Glycosaminoglycans (GAGs) are present as structure of bone ECM, forming 
proteoglycans. Examples of those molecules include hyaluronic acid, which is naturally 
present in bone [240] and chondroitin sulfate [241]. Marine-origin molecules with high 
similarity to GAGs, as chitosan [242], and highly tailorable algae-derived products as 
agarose and alginate have also seen application in the bone tissue regeneration field [243].  
37 
 
A wide range of natural origin polymers is used either because they are prepared from 
ECM proteins (see Table 1 for a list of relevant bone ECM proteins), e.g. collagen 
I/CHondro-Gide® (Geitlisch Pharma) and hyaluronan [2], or due to their structural 
similarity with ECM components [2]. Also, the implantation of acellular scaffolds, derived 
from decellularized allogenic or xenogenic tissues, has also been suggested for bone tissue 
regeneration [2].  
To sustain cells for bone tissue regeneration, biomaterials have been processed in a high 
number of manners, which include the most common porous scaffolds, hydrogels and 
microparticles [5]. For the design of biomaterials for specific applications, a balance 
between their chemical/biochemical cues and physical properties (e.g. Stiffness, porosity, 
energy dissipation ability) needs to be kept. Together, all different cues exposed to cells 
and to the surrounding tissue contribute for the right conditions to be meet for tissue 
integration and induction of osteogenesis/bone regeneration [244-246].   
The role of biomaterials in tissue engineering has evolved from classical cell-supporting 
structures to highly functional devices, designed specifically to induce a desired response, 
along with features for easy implantation, integration in the tissue, among others. In a 
recent example, Zhang et al. (1946) [247] created hydroxyapatite (HA) and amphiphilic 
poly(lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(lactide-co-glycolide) (PELGA) 
composites membranes with tunable decomposition rates. Such structures were stiffened 
when hydrated (due to enhanced PEG crystallization) and then recover their shape at body 
temperature, which enabled an efficient skeletal progenitor cells delivery to bone grafts. 
This HA-PELGA composite promoted the proliferation, attachment and osteogenesis of 
periosteum-derived cells in vitro. When implanted on a rat model, it facilitated the 
transference of confluent cell sheets of protein-labeled bone marrow mesenchymal stem 
cells (BMMSCs). Due to their shape memory behavior influenced by physiological 
temperatures, these membranes could be automatically folded in a tubular configuration, 
being distorted into a flat temporary shape that allowed for a better cell seeding/cell sheet 
transfer. Therefore, these membranes are promising smart materials for the usage of 
synthetic periosteal membranes in allograft healing.  
Unlike soft tissue engineering, in which hydrogels with mechanical properties comparable 
to the ones of the native tissues have been developed, the fabrication of tough hydrogels 
with adequate mechanical properties to sustain loads present in bone is a recent trend. 
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Nonoyama et al. [248] used a double network tough hydrogel with in-gel precipitated 
hydroxyapatite for rat bone defects. The toughness of the hydrogel was conferred by the 
combination of a brittle (poly(2-acrylamido-2-methyl propanesulfonic acid)) and a ductile 
(poly( N,N -dimethylacrylamide)) network. Such biomaterial showed a robust bonding to 
the defected bones and its mechanically properties increased significantly as compared to 
an implanted non-mineralized hydrogel.  
Biomaterials are often chemically modified [5] or impregnated/loaded with bone 
differentiation and formation-related molecules [5] to induce a specific bone regeneration 
response. A recent example by Lee et al. (1946) [249] focuses on the use of three-
dimensional (3D) printed polycaprolactone (PCL) engrafted with a recombinant human 
bone morphogenic protein-2 (rhBMP2) through polydopamine (DOPA). The release of the 
rhBMP-2 was sustained up to 28 days and in vitro studies using a pre-osteoblast cell line 
showed the ability of such scaffold to induce cell proliferation and differentiation  
Besides polymeric materials and their respective composites, graphene-based biomaterials, 
namely membranes and porous structures [250], have shown promising results in the 
treatment of bone defects. Although in this section the focus is mainly the use of polymeric 
materials for bone regeneration, the importance of such novel materials must also be 
acknowledged. 
 
7.1.2. Cells in tissue engineering strategies for bone regeneration 
In bone regeneration, cells are often included as part of a therapy, as they naturally 
synthesize ECM proteins responsible for the tissue reshaping. 
In the tissue engineering field, osteoprogenitor cells that can differentiate into osteoblasts 
are mostly used [2]. Due to their multipotency, MSCs have been widely used in tissue 
engineering. They are usually extracted from bone marrow (BMMSCs) [251], and can be 
isolated, stimulated to expand to various tissues and expanded in culture [252]. They also 
can be retrieved with high yields after isolation from adipose tissues collected during 
liposuctions [253]. 
The regulation of bone function is dependent on the correct regulation of the crosstalk 
between a wide plethora of cells, as shown in Section 5. A study performed using MSCs, 
by Birmimgham et al (1942) [254] proved the role of the biochemical signaling between 
bone cells (osteocytes and osteoblasts) and MSCs, to lead osteogenic differentiation. To 
39 
 
determine the osteogenic differentiation, the alkaline phosphatase (ALP) activity was 
monitorized, as well as the calcium deposition, as well as the number of cells. The results 
showed that ALP peaked earlier, and a great calcium deposition was observed when the 
MSCs were co-cultured with osteocytes, rather than with osteoblasts. Ultimately, this finds 
suggest a need for a relationship with osteocytes and osteoblasts for the MSCs signaling 
differentiation pathway. The use of co-cultures for bone tissue regeneration induction, 
seems to be a good methodology to use in the clinical field. 
Jeon et al. (1946) [255], used human induced pluripotent stem cells (hiPSC), a pluripotent 
stem cell type generated directly from human adult cells, that can create specific 
mesenchymal and macrophage precursors [256] to induce osteoblast and osteoclast 
differentiation. Both cell types, involved in bone resorption and formation (see Section 5), 
combined with HA-coated poly(lactic-co-glycolic acid)/poly(L-lactic acid) (HA–
PLGA/PLLA) scaffolds, were tested in different concentrations.  The 5% w/v HA-coated 
polymer allowed recapitulating major aspects of the tissue remodeling process of human 
bone in vitro. Afterward, the co-cultured hiPSC-MSC/-macrophage system was implanted 
(after culture on the scaffolds) in rodents, forming bone-like mature tissue. This study 
showed the importance of the osteoprogenitor cells-induced matrix deposition and tissue 
resorption conjugated with immunomodulation, to allow a better-quality tissue formation.  
 
7.1.3. Physical stimuli for bone regeneration 
As revised in Sections 1 and 2, healthy bone is exposed to stresses in a daily basis. Given 
that this compromises the bone environment, to promote a proliferation and differentiation 
of the niche cells, this mechanical loading needs to be replicated in tissue engineering 
[257]. Bioreactors allow mimicking such in vivo-occurring stimuli. Different types of 
bioreactors allow stimulating cells in distinct manners by inducing shear stress and flow 
perfusion, hydrostatic pressure and compression [258].  
Spinner flasks are a basic bioreactor type, that allow an efficient mixture of oxygen and 
nutrients in the medium. In a specific bioreactor design adapted to the use of biomaterials, 
the scaffolds/samples were suspended using needles in a contained flask with the medium. 
Through the experiment, the scaffolds/samples were kept in place, while the medium was 
agitated with the use of a magnetic stirrer. The results obtained using this bioreactor 
showed that the system is promising for cell differentiation and proliferation, when 
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compared with static conditions [259]. Figure 8 shows a schematic representation of this 
bioreactor. However, spinner flasks have showed some limitations on mass transference, as 
the flow is too low to induce a homogeneous distribution of the cells by the scaffolds, 
residing manly on the periphery of the construct [260].   
 
Figure 8- Spinner flask scheme. I) vessel, II) cells/scaffold; III) needles used to maintain 
the scaffolds in position, IV) magnetic stir bar (taken from Sladkova, M., & de Peppo, G. 
M. (2014) [260] 
 
Another type of bioreactor – the rotating wall bioreactor - was created with the intention of 
keeping the cell culture protected from high forces during an experiment. Unlike spinner 
flasks, the scaffolds are completely free to move within the vessel (with medium) [261]. It 
is composed of chamber, shaped like a cylinder, where the walls (inner and outer, or both) 
can rotate in a constant angular speed [261] (see figure 9 for a schematic of this 
bioreactor). The velocity of the rotation speed allows for a balance between the 
gravitational and hydrodynamic drag forces, which allows for the scaffolds to be suspense 
on the medium [262]. As the tissue starts to growth, it is needed to increase the rotation, so 
that the previous balance can be maintained [263]. Like spinner flasks, rotating wall 
bioreactors allow for a better medium transportation than static 3D cell culture, as well as 
for a better cell distribution [259,264].  
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Figure 9- Rotating wall bioreactor scheme. I) rotating wall vessel, II) cylinders, III) 
Cells/Scaffolds, IV) rotator base (taken from Sladkova & de Peppo (2014) [260]  
 
 
Spinner flasks and rotating walls have shown several limitations regarding medium 
perfusion into biomaterials. Flow perfusion bioreactors are constructed to surpass such 
problem. Using a perfusion pump, they allow a perfusion to occur in the system, and thus, 
for the medium to correctly flow through the scaffold [264]. The most basic perfusion 
bioreactor system consists of a perfusion pump, tubing to make the circuit, a chamber for 
the scaffold, and a media reservoir [265] (see figure 10 for a schematic of this bioreactor).  
The perfusion is also guaranteed by the chamber in which the scaffold is contained, since it 
is made in a way that the medium should flow right through the construct [261].  
Perfusion bioreactors allow uniform medium mixture, so they are preferred in the tissue 
engineering field as they provide an optimized control of the dynamic cell culture process 
(environmental and cells stimulation) [264]. This is achieved by using a pump that 
circulates the media in the system, mimicking, as close as possible, the natural 
environment of the cells in the human body [265]. One of the conditions that flow 
perfusion bioreactors allow achieving is shear stress stimulation, which happens very often 
in the human body. Shear stress occurs in the bone, associated with the blood circulation, 
in a parallel fashion to the surface of the bone [266].  
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Figure 10-Perfusion bioreactor scheme. I) culture chamber, II) cells/scaffold, III) culture 
medium reservoir, IV) peristaltic pump, V) tubbing system (taken from Sladkova & de 
Peppo (2014) [260]. 
 
Bone´s microenvironment is conditioned by physical aspects, such as: bending, tension, 
torsion, bending, shear and compression. Compression bioreactors are usually allied with 
perfusion, which leads to an augmentation of the expression of osteogenic markers (eg: 
ALP) [267]. This bioreactor type consists of a motor, a controller, for the different 
magnitudes and frequencies to use, and a linear motion type system [268] (see figure 11 for 
a schematic of this bioreactor.)  The scaffold with the cells is put on a plate, and the piston 
that is going to apply the force is compressed against the material [268]. This load 
transference should be made using flat plates, for an even load distribution. If that is not 
possible (as the case for multiple scaffolds), then the scaffolds should have similar heights 
[269].  
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Figure 11- Compression bioreactor work schematics. I) compression chamber, II) 
cell/scaffold, III) piston (taken from Sladkova & de Peppo (2014) [260].  
 
7.1.4. Biomolecules for bone regeneration 
Biomolecules are essential in the bone regeneration process. As discussed in section 7, 
they are responsible for the recruitment, proliferation, differentiation and migration of the 
osteoprogenitor cells [2]. They are present constantly through all the bone phases, from 
formation to healing [2]. As it was mentioned before on section 4, upon bone injury, 
immune cells are recruited to the defect site coordinate actions triggered by the expression 
of cytokines and growth factors, that culminate in the recruitment of MSCs, remodeling 
and vascularization of the tissue [2]. BMPs are the most widely studied growth factors for 
bone tissue engineering. BMP-2 and BMP-7 are the most used ones, and have seen 
application in clinical medicine. However, they have showed limited success, owing to the 
reported formation of ectopic bone, as well as their high cost [269]. The release of 
bioactive molecules in a controlled and site-specific manner are crucial for the success of 
tissue engineering strategies. Herein, we will not focus on such strategies, that are 
described in reviews as [270], [271] and [272].  
Besides soluble molecules produced during bone healing, insoluble molecules comprised 
in the bone ECM, namely proteins, are of utmost importance for the achievement of 
effective regeneration. Also, molecules mediating cell-cell contact have shown to have 
adjuvant and inhibiting effects on bone cell differentiation [2]. A study by Cosgrove et al 
(1946) [9] describes the use of a biomaterial-based approach to elucidate the role of cell-
ECM and cell-cell contact of mesenchymal stem cells in osteogenesis driven by 
mechanical transduction phenomenon. The authors modified a hyaluronic acid hydrogel 
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with an HAVDI adhesive motif from N-cadherin (to emulate the cell-cell ligation) and a 
RGD adhesive motif from fibronectin (to emulate the cell-ECM ligation), for the co-
presentation of these motifs. HAVDI ligation decreased the contractible state of the cells 
(and the nuclear YAP/TAZ location), which led cells to wrongly interpret the ECM 
stiffness, causing a change in the downstream cell osteogenic differentiation and 
proliferation.  
In the study made by Dolatshahi-Pirouz et al (1944) [141] the authors tested several stem 
cell-biomaterial interactions in a high-throughput approach. Biomaterials comprised 
gelatin and an array of ECM proteins, dispensed in a combinatorial manner. With such a 
3D hMSCs-laden gel microarray, several ECM protein combinations were assessed for 
their role in the induction of osteogenic differentiation. Formulations containing combined 
ECM proteins in their composition led to more pronounced osteodifferentition, mainly in 
the presence of the soluble factor BMP-2 in the medium. The use of high-throughput 
screening strategies allowed the multiplexed screening of biomaterials conditions, in a 
rapid and cost-effective manner.  
 
7.2. Current multifactorial approaches targeting bone regeneration  
Although several tissue engineering therapies for bone regeneration focus on unifactorial 
approaches, as reported in the previous section, novel approaches with a multifactorial 
approach have been developed in the last years. The study of isolated variables is of 
extreme importance to unravel biological effects, and has allowed the incorporation of 
each factor in multifactorial complex studies. However, there are few studies that consider 
a wide range of factors that contribute to the bone microenvironment (e.g. shear stress/flow 
perfusion, strain/compression, cell-cell interactions, characteristic extracellular matrix: 
mineralized and non-mineralized, ECM-cells interactions, soluble and insoluble factor 
interactions, cell-cell contact). Novel multidimensional approaches that enable a high-
throughput screening analysis of a great plethora of these factors, as it can be seen in the 
following scheme, are in need. This may be obtained by the design and implementation of 
devices that (i) integrate highly functional biomaterials that replicate the native bone 
composition, (ii) allow culturing cells that can differentiate into multiple lineages of the 
bone, and (iii) permit the exposure of cell-biomaterials constructs to physiologically 
relevant mechanical forces. 
45 
 
 
Figure 12-  Summary scheme containing diverse factors that a device to use in bone tissue 
engineering should comprehend. 
 
8. Conclusion 
Bone tissue engineering has a high degree of complexity, due to the microenvironment of 
the native tissue. The bone modeling and remodeling that happens throughout an 
individual’s life cycle helps preserving this structure, which is important for motion as well 
for the protection of other organs and tissues. Current tissue engineering techniques have 
shown to be very promising. However, they remain mostly unifactorial, not considering all 
the diverse interactions and stimuli occurring during bone formation and resorption. 
Therefore, novel techniques need to be discovered and implemented in the regenerative 
medicine field for the clinical treatment of bone fractures, either caused due to a disease or 
physical caused fracture.  
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1. Objectives 
 
1.1. Main objective 
 
The main objective of this study was the validation and development of a perfusion bioreactor 
for the high-throughput analysis of biomaterials/stem cells combinations. 
 
1.2. Secondary objectives 
 
✓ Development of an arrayed hollow platform with 3D porous biomaterials 
✓ Biomaterial modification with 32 different combinations of proteins  
✓ Assembly of a bioreactor using widely available labware 
2. Materials and methods 
2.1. Preparation of hollow arrayed platform 
A polydimethylsiloxane (PDMS, Elastomer Kit, Dow Corning) solution in a ratio of 5:1 
(PDMS:curing agent) was prepared and degassed under vacuum for 1 hour.  A volume of 3 mL was 
pipetted onto a mold, schematically represented on Figure 1. The molds containing the PDMS 
solution were again degassed under vacuum for 1 hour, and cured in an oven (Oven/Laboratory 
dryer, Ecocell 55 Frilabo), at 70ºC for 1 hour. The hollow PDMS structure shown in Figure 2 was 
obtained after removing the cured PDMS from the mold using tweezers. The final platform had 
approximately 2 mm height and 4 x 4 cm2 area. The hollowed platform had 1 mm diameter circular 
by 1 mm, as represented in Figure 1.   
2.2. Microarrayed platforms containing chitosan scaffolds 
A 0.9% chitosan (Sigma-Aldrich) solution was prepared using glacial acetic acid (LabChem) at 1% 
(w/v). We tested several chitosan concentrations, from the range of 0,125% to 1%. We chose 0,9% 
in the end, since this was the concentration that allowed the construction of a porous and robust 
scaffold, for the previously mentioned concentration range. A volume of 3 μL was pipetted onto 
individual wells of the PDMS platform.  The platform containing chitosan solution in the wells was 
frozen at -20ºC for 4 hours, and then freeze-dried (LyoQuest Plus Eco,VWR) overnight. The 
scaffolds were then neutralized by adding droplets of 1 M sodium hydroxide (NaOH, Eka, 
AkzoNobel) solution prepared in 70% (%vol) ethanol (Valente & Ribeiro). Different neutralization 
and washing approaches were developed and optimized to minimize chitosan scaffolds shrinking 
after neutralization. After 10 minutes neutralization, scaffolds were washed with distilled water for 
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30 minutes (the water was changed three times). The samples were frozen again at -20ºC for 4 
hours and freeze-dried overnight. The platforms were sterilized prior to cell culture by exposure to 
UV irradiation for 30 minutes in each side of the device (Laminar Flow Cabinet S@femate Eco 
1.2m, EuroClone®). 
 
 
 
Figure 1- (A) Schematic representation of the assembled bioreactor. (B) Final aspect of an assembled bioreactor, 
with two experiments taking place at the same time. (C) Schematic modification of the 3D scaffolds in the hollow 
arrays 
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Figure 2- Picture of a hollow platform. Each individual spot was later filled with chitosan solution, to prepare a 
minaturized porous scaffold.  
 
2.3. Preparation of protein solutions 
Five human proteins were used in this study: fibronectin (F, Sigma Aldrich), vitronectin (V, Sigma 
Aldrich), E-cadherin (E, Advanced BioMatrix), collagen type I (C, Sigma Aldrich) and amelogenin 
(A, Abcam). Solutions of the 5 proteins were prepared by dissolution of the stock solution in a 
phosphate buffered saline solution (PBS, ThermoScientific). The protein solutions were all diluted 
to the same final concentration, 0.05 mg/mL. Protein solutions used for immobilization on chitosan 
scaffolds were prepared with equal proportions of each protein. The final protein solutions had the 
same final mass of protein. 
2.4. Protein immobilization onto miniaturized chitosan 3D scaffolds 
Solutions of N-Hydroxysuccinimide (NHS, Aldrich Laborspirit) and N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, Sigma (Fluka)) were 
added to the protein solutions, in a proportion of 1:1:2, (v/v) EDC-NHS:protein solution, 
accordingly to a previously reported method [1]. EDC and NHS concentrations in the protein 
solutions were 2 mM and 5 mM, respectively. A volume of 1 μL of each protein mixture was 
pipetted onto single scaffolds, and left to react for one hour at room temperature. The chips 
were then washed three times in sterile PBS.  
The covalent immobilization of the proteins to the scaffolds was crucial, since in preliminary 
approaches consisting in the physical adsorption of the proteins to the scaffolds, we observed 
a complete loss of adhered cells to the scaffolds after a 3-day time point. The reasons for 
proteins activity loss and eventual cell detachment on this approach were not explored in this 
work.  
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2.5. Cell expansion 
Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs) were purchased from LGC Standards, 
ATCC. The undifferentiated cells were cultured and expanded under basal condition, using 
Minimum Essential alpha Medium (alpha-MEM, Sigma, USA), supplemented with 10% (v/v) fetal 
bovine serum (ThermoFisher Scientific) and 1% (v/v) penicillin-streptomycin.  
2.6. Cell seeding  
A 5000 cells/μL BMSCs suspension was pipetted, at a volume of 1 μL, onto the scaffolds with 
previously immobilized proteins. Cells were left to attach to the material for 30 min at 37ºC. After 
this seeding step, the chips were washed once with PBS and incubated (CO2 Incubator, Model 
C170, Binder) at 37ºC, 5% CO2, in cell supplemented culture medium. Cells were used on passages 
of P2 to P6, and cell culture was exchanged every 2 days. 
 
2.7. Bioreactor assembly  
A perfusion bioreactor (figure 1) was assembled to withstand parallel replicates of each individual 
setup depending solely on the available channels of the peristaltic pump used to perfuse the 
medium. Each individual set of the bioreactor comprised: (i) one chamber with cell culture medium 
and capable of holding the hollow PDMS platform containing 3D scaffolds arrays and respective 
adhered cells, (ii) tubes (Tygon ST R3607, Ismatec, 3.17 mm outer diameter) for medium 
transportation, (iii) one reservoir of cell culture medium (Schott, 250 mL), and (iv) one peristaltic 
pump (REGLO digital MS-2/6-160) (figure 1). The tubes were connected to the cell culture 
medium reservoir through a commercially available screw cap (Screw cap HPLC, GL 45, 4 ports, 
Duran®) with four ports (3.0 mm diameter). The inlet tube, that drove medium flux to the 
bioreactor chamber, was inserted inside the cell culture medium; the outlet tube, which recirculated 
the cell culture medium back to the reservoir, was left about 1 cm above the cell culture medium 
meniscus. The tubes connecting the medium reservoir and the bioreactor chamber were assembled 
in the channels of a peristaltic pump. Gas exchange in the cell culture medium was promoted 
through the assembly of two 0.2 μm sterile cellulose acetate syringe filters (30 mm diameter; 
WhatmannTM/GE Healthcare) in the two remaining entries of the reservoir cap. The bioreactor 
chamber was composed of two sterile 20 mL polypropylene syringes (VWR) without the respective 
pistons. Tubes were connected to the outlet of the syringes, and both syringes were assembled 
together containing the perforated arrayed platform in between both syringes. The chamber was 
sealed using sterile Parafilm® and insulation tape on outer layers. All tube-tube and syringe-tube 
junctions were also sealed with Parafilm® and insulation tape. The schematic representation of the 
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bioreactor assembly is depicted in Figure 1A. A picture of the bioreactor containing two parallel 
setups, assembled to the same peristaltic pump, can be seen in Figure 1B.  
 
2.8. Dynamic and static (control) cell culture 
The arrayed platforms containing seeded cells were placed in the bioreactor chamber using sterile 
tweezers. BMSCs were cultured in the platforms for 24 hours, under static conditions, prior to the 
assembly in the bioreactor. For static control experiments, cell culture was continued under static 
conditions inside suspension Petri dishes, with 8 mL supplemented cell culture medium. On 
dynamic culture, after the complete bioreactor sealing, the bioreactor reservoirs and chambers were 
placed on an incubator at 37ºC and 5% CO2. The bioreactor chambers were placed in a horizontal 
position. The peristaltic pump was set with a flow of 0.68 mL/min. This flow is in a range of 0.2 – 1 
mL/min, previously shown by Bancroft et al. [2] to induce BMSCs cell growth, proliferation and 
differentiation into the osteogenic lineage on two-dimensional cell culture conditions. The 
experiments were then carried out for 24 hours and 5 days of incubation. To remove the scaffold 
arrays from the bioreactor, the parafilm® and insulating tape shell used to seal the syringes chamber 
was cut, inside a laminar flow chamber, with a sterile scalpel. The platform was then carefully 
removed using sterile tweezers. All scaffold arrays were washed with sterile PBS, and immediately 
analyzed for cell viability. 
2.9. Live/Dead analysis 
The scaffold arrays retrieved from static and dynamic cell culture were immersed in 2 mL of sterile 
PBS containing 4 μL of calcein AM (Thermo Fisher Scientific) and 2 μL of propidium iodide (PI, 
Thermo Fisher Scientific) in the incubator at 37ºC, 5% CO2, for 30 minutes. The platforms were 
then analyzed using a fluorescence microscope (Axio Imager M2, Zeiss) with both EGFP/PI filters, 
at a fixed exposure time of 800 ms. Images were acquired in each individual spot of the platform, 
and tiled automated high-content image acquisition of whole chips was also performed. After the 
analysis, the chips were fixed with formalin at 4% (Sigma), at 4ºC, for 24 hours. The semi-
quantitative results for calcein AM signal quantification were calculated by dividing the detected 
intensity in each formulation by the one detected in the protein-free control in each individual time 
point. Higher ratios represented conditions with higher detected calcein AM signal. 
2.10. ALP quatification analysis 
After fixation with formalin, the platforms were washed twice with distilled water for 30 minutes, 
and then immersed in a ALP substract solution (1-Step™ NBT/BCIP Substrate Solution, 
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ThermoScientific). The reaction took place at 37ºC, for 4 hours. The ALP present in the array was 
stained in purple. However, a method based on fluorescence analysis was developed to perform 
rapid and easy analyses of ALP presence in each individual scaffold. Whole platform images were 
acquired automatically using a fluorescence microscope equipped with a xyz-controlled table, at an 
exposure time of 60 ms, using the EGFP filter. The whole array and scaffolds have 
autofluorescence. The places stained for ALP show a non-fluorescent signal, and black spots can be 
observed in the exact places where ALP is visibly stained. The relative semi-quantitative 
assessment of ALP per scaffold was performed by increasing the fluorescent signal of the all 
images equally, and by quantifying the fluorescent signal in each individual scaffold. Scaffolds with 
lower detected fluorescence were the ones with higher amounts of ALP. The semi-quantitative 
results for ALP quantification were calculated by dividing the detected intensity in each formulation 
by the one detected in the protein-free control. Lower ratios represented conditions with higher 
amount of detected ALP. 
References 
[1] Custódio, C. A., Alves, C. M., Reis, R. L., & Mano, J. F. (2010). Immobilization of 
fibronectin in chitosan substrates improves cell adhesion and proliferation. Journal of tissue 
engineering and regenerative medicine, 4(4), 316-323. 
[2] Bancroft, G. N., Sikavitsas, V. I., Van Den Dolder, J., Sheffield, T. L., Ambrose, C. G., 
Jansen, J. A., & Mikos, A. G. (2002). Fluid flow increases mineralized matrix deposition in 
3D perfusion culture of marrow stromal osteoblasts in a dose-dependent manner. Proceedings 
of the National Academy of Sciences, 99(20), 12600-12605. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter III- Design of a perfusion 
bioreactor for the high-throughput 
analysis of combinations of ECM 
proteins on human mesenchymal 
stem cells behaviour in dynamic 3D 
conditions 
 
 
 
 
 
72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
Screening for the combined influence of protein microenvironments and flow perfusion on the adhesion and 
osteogenic commitment of mesenchymal stem cells on 3D scaffolds 
Diana Lopes1, Mariana B. Oliveira1*, João F. Mano1* 
1 Department of Chemistry, CICECO – Aveiro Institute of Materials. 3810- Aveiro. 
*Corresponding author e-mail: mboliveira@ua.pt, jmano@ua.pt 
 
Abstract 
Extracellular matrix (ECM) and cell-cell adhesion mediating proteins have been used to tailor stem 
cells biological response. Bioinspired biomaterial models that combine different proteins and 
modulate biophysical aspects co-relatable with the native ECM have been explored for cell 
expansion and differentiation purposes, both in traditional 2D and closer-to-native niche 3D models. 
Despite the efforts to understand crucial effects of tissue native niches, biomaterials multivariate 
arrays often lack the ability to emulate dynamic mechanical aspects that occur in specific biological 
milieus. Although there is in vitro evidence of the adjuvant role of biomimetic flow enabling stem 
cells to differentiate into different lineages, the screening of rationally designed large arrays of 
ECM-like 3D matrices stimulated by in vivo-mimetic mechanical stimulation is still needed. Here, a 
system comprising a tailor-made bioreactor and 32 different biomaterial combinations based on the 
ECM and cell-cell contact proteins is assembled to study mesenchymal stem cells (MSCs) adhesion 
and alkaline phosphatase (ALP) expression under flow perfusion. The bioreactor was assembled 
from widely available affordable labware, and permitted retrieved data from 32 experimental 
conditions in a single experiment. This system may find applications in the development of 
biomaterials for tissue regeneration and as a disease model platform. 
 
1. Introduction 
The poor isolation of the role of individual factors and their respective interplay affecting human 
tissues healing processes hinders the development of simplified, yet relevant and effective, 
implantable tissue engineering systems and in vitro testing devices [1]. Although bioinspiration can 
be a powerful source to drive novel biomaterial designs, the rational and controlled testing of 
compositional variates and their synergic role with other native niche aspects (such as mechanical 
stimuli) is necessary to successfully combine biology know-how and the design of effective 
engineering systems [2]. The extracellular matrix (ECM) is accepted as a cornerstone aspect for the 
maintenance of tissues function and regeneration capability [3], because it is the three-dimensional 
(3D) matter that embeds cells and, besides providing mechanical cues and physical/structural 
support to tissues [4], is composed of molecules secreted by the tissues’ own cells and regulates 
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several signaling pathways [3]. Such phenomena involve cell-cell and cell-matrix adhesion 
mediation proteins, which also have significant roles in the recruitment and binding of growth 
factors that trigger signaling cascades, commonly involved in cell differentiation signaling [4]. 
ECM structural and biochemical properties are, in part, dictated by distinct protein contents, which 
closely relate with defined functional properties of each tissue.  One of the most common 
limitations associated with in vitro studies targeting tissue regeneration is the standard 2D culture 
conditions adopted to test the potential of biomaterials. It has been proven, though, that mimicking 
the 3D structure of native ECM is of utmost importance to achieve in vitro/in vivo correlating 
results [5-7]. As such, to fully understand the complexity dictating regeneration, target aspects of 
tissue 3D microenvironments need to be identified and emulated in vitro [8-11].  
Mechanical factors have proven to be a powerful adjuvant of regeneration techniques [12]. Such 
stimuli occur naturally in human tissues and their application is highly relevant for the development 
of in vitro regeneration strategies [13]. Bioreactors are a useful tool due to their ability to maintain 
3D ECM-mimetic constructs under stress [14]. Perfusion bioreactors enhance the homogeneous 
distribution of the cells inside scaffolds, and provide increased fluid circulation inside the 
biomaterial structure, providing high oxygen and nutrients availability to cells [15,16]. These 
systems can be operated in a continuous way, allowing a continuous shear flow stimulation [17,18] 
and/or consistent medium perfusion through the scaffolds [19]. Bancroft et al.  described for the 
first time the use of a perfusion bioreactor for stem cells stimulation while seeded on 3D polymeric 
scaffolds targeting bone regeneration [20]. Healthy bone remodels in response to mechanical 
stresses: in the absence of loading bone resorption is increased, while in its presence - felt by cells 
as flow perfusion through the movement of extracellular fluid radially toward the bone cortex [21] -
, bone is known to remodel. Subsequent studies focusing on the role of perfusion on primary bone 
cells and stem cells behavior have shown increased mineralized matrix deposition in a dose-
dependent manner [22-24].  
High-throughput screening techniques have allowed the multivariate testing of tissue engineering 
systems, in a cost- and time-saving manner [25-30]. Targeting bone regeneration and ECM proteins 
combinations, Dolatshahi-Pirouz et al. designed a high-throughput system using type-I collagen 
hydrogels loaded with combinations of ECM proteins, including fibronectin, vitronectin, laminin 
and osteocalcin. The effect of pro-osteogenic soluble growth factors on the system was also 
assessed on the osteogenic differentiation of bone marrow-derived stem cells (MSCs) [31]. Other 
high-throughput screening platforms were used to assess the osteogenic potential of biomaterials 
[32-35]. Although these studies provided valuable information about biomaterials composition and 
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cellular responses, all these experiments were performed under static cell culture conditions. The 
combined effect of dynamic flow and biomaterials composition on the triggering of cellular 
responses is still poorly explored, as flow perfusion studies have been limited to experiments using 
a low number of conditions. 
Here, we report the design of a novel device that allowed performing a high-throughput study of the 
role of 32 ECM proteins combinations along with a continuous perfusion stimulus. Chitosan 
scaffolds with average diameter of 1 mm were patterned on a poly(dimethylsiloxane) hollow 
platform. Each individual scaffold was chemically modified with different protein combinations, 
comprising mixtures of ECM adhesive proteins (fibronectin - F, vitronectin - V and type I collagen 
- C), cell-cell contact protein (E-cadherin - E) and an enamel ECM protein (amelogenin - A). MSCs 
were seeded on each individual scaffold, and the role of each protein combination under (i) static 
conditions and (ii) flow perfusion conditions (at a flow rate of 0.03 mL/min) were assessed for cell 
adhesion and osteogenic early marker alkaline phosphatase (ALP) expression after 1 and 5 days of 
cell culture. The dynamic environment was achieved by the construction of a bioreactor, using 
regular labware materials, by a simple assembly and of low cost construction. The technology 
reported herein allowed disclosing combined effects of dynamic perfusion environments with 
combinatorial biomaterial compositions on stem cells differentiation.     
2. Materials and methods 
2.1. Preparation of hollow arrayed platform 
A polydimethylsiloxane (PDMS, Elastomer Kit, Dow Corning) solution in a ratio of 5:1 
(PDMS:curing agent) was prepared and degassed under vacuum for 1 hour.  A volume of 3 mL was 
pipetted onto a mold, schematically represented on Figure 1. The molds containing the PDMS 
solution were again degassed under vacuum for 1 hour, and cured in an oven (Oven/Laboratory 
dryer, Ecocell 55 Frilabo), at 70ºC for 1 hour. The final platform had approximately 2 mm height 
and 4 x 4 cm2 area. The hollowed had 1 mm diameter circular by 1 mm, as represented in Figure 1.   
2.2. Microarrayed platforms containing chitosan scaffolds 
A 0.9% chitosan (Sigma-Aldrich) solution was prepared using glacial acetic acid (LabChem) at 1% 
(w/v). A volume of 3 μL was pipetted onto individual wells of the PDMS platform.  The platform 
containing chitosan solution in the wells was frozen at -20ºC for 4 hours, and then freeze-dried 
(LyoQuest Plus Eco,VWR) overnight. The scaffolds were then neutralized by adding droplets of 1 
M sodium hydroxide (NaOH, Eka, AkzoNobel) solution prepared in 70% (%vol) ethanol (Valente 
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& Ribeiro). After 10 minutes neutralization, they were washed with distilled water for 30 minutes 
(the water was changed three times). The samples were frozen again at -20ºC for 4 hours and 
freeze-dried overnight. The platforms were sterilized prior to cell culture by exposure to UV 
irradiation for 30 minutes in each side of the device (Laminar Flow Cabinet S@femate Eco 1.2m, 
EuroClone®). 
2.3. Preparation of protein solutions 
Five human proteins were used in this study: fibronectin (F, Sigma Aldrich), vitronectin (V, Sigma 
Aldrich), E-cadherin (E, Advanced BioMatrix), collagen type I (C, Sigma Aldrich) and amelogenin 
(A, Abcam). Solutions of the 5 proteins were prepared by dissolution of the stock solution in a 
phosphate buffered saline solution (PBS, ThermoScientific). The protein solutions were all diluted 
to the same final concentration, 0.05 mg/mL. Protein solutions used for immobilization on chitosan 
scaffolds were prepared with equal proportions of each protein. The final protein solutions had the 
same final mass of protein. 
2.4. Protein immobilization onto miniaturized chitosan 3D scaffolds 
Solutions of N-Hydroxysuccinimide (NHS, Aldrich Laborspirit) and N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, Sigma (Fluka)) were 
added to the protein solutions, in a proportion of 1:1:2, (v/v) EDC-NHS:protein solution, 
accordingly to a previously reported method [36]. EDC and NHS concentrations in the protein 
solutions were 2 mM and 5 mM, respectively. A volume of 1 μL of each protein mixture was 
pipetted onto single scaffolds, and left to react for one hour at room temperature. The chips 
were then washed three times in sterile PBS. 
2.5. Cell expansion 
Bone Marrow-Derived Mesenchymal Stem Cells (BMSCs) were purchased from LGC Standards, 
ATCC. The undifferentiated cells were cultured and expanded under basal condition, using 
Minimum Essential alpha Medium (alpha-MEM, Sigma, USA), supplemented with 10% (v/v) fetal 
bovine serum (ThermoFisher Scientific) and 1% (v/v) penicillin-streptomycin.  
2.6. Cell seeding  
A 5000 cells/μL BMSCs suspension was pipetted, at a volume of 1 μL, onto the scaffolds with 
previously immobilized proteins. Cells were left to attach to the material for 30 min at 37ºC. After 
this seeding step, the chips were washed once with PBS and incubated (CO2 Incubator, Model 
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C170, Binder) at 37ºC, 5% CO2, in cell supplemented culture medium. Cells were used on passages 
of P2 to P6, and cell culture medium was exchanged every 2 days. 
 
2.7. Bioreactor assembly  
A perfusion bioreactor (figure 1) was assembled to withstand parallel replicates of each individual 
setup depending solely on the available channels of the peristaltic pump used to perfuse the 
medium. Each individual set of the bioreactor comprised: (i) one chamber with cell culture medium 
and capable of holding the hollow PDMS platform containing 3D scaffolds arrays and respective 
adhered cells, (ii) tubes (Tygon ST R3607, Ismatec, 3.17 mm outer diameter) for medium 
transportation, (iii) one reservoir of cell culture medium (Schott, 250 mL), and (iv) one peristaltic 
pump (REGLO digital MS-2/6-160). The tubes were connected to the cell culture medium reservoir 
through a commercially available screw cap (Screw cap HPLC, GL 45, 4 ports, Duran®) with four 
ports (3.0 mm diameter). The inlet tube, that drove medium flux to the bioreactor chamber, was 
inserted inside the cell culture medium; the outlet tube, which recirculated the cell culture medium 
back to the reservoir, was left about 1 cm above the cell culture medium meniscus. The tubes 
connecting the medium reservoir and the bioreactor chamber were assembled in the channels of a 
peristaltic pump. Gas exchange in the cell culture medium was promoted through the assembly of 
two 0.2 μm sterile cellulose acetate syringe filters (30 mm diameter; WhatmannTM/GE Healthcare) 
in the two remaining entries of the reservoir cap. The bioreactor chamber was composed of two 
sterile 20 mL polypropylene syringes (VWR) without the respective pistons. Tubes were connected 
to the outlet of the syringes, and both syringes were assembled together containing the perforated 
arrayed platform in between both syringes. The chamber was sealed using sterile Parafilm® and 
insulation tape on outer layers. All tube-tube and syringe-tube junctions were also sealed with 
Parafilm® and insulation tape. The schematic representation of the bioreactor assembly is depicted 
in Figure 1A. A picture of the bioreactor containing two parallel setups, assembled to the same 
peristaltic pump, can be seen in Figure 1B.  
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Figure 1- (A) Schematic representation of the assembled bioreactor. (B) Final aspect of an assembled bioreactor, 
with two experiments taking place at the same time. (C) Schematic modification of the 3D scaffolds in the hollow 
arrays 
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2.8. Dynamic and static (control) cell culture 
The arrayed platforms containing seeded cells were placed in the bioreactor chamber using sterile 
tweezers. BMSCs were cultured in the platforms for 24 hours, under static conditions, prior to the 
assembly in the bioreactor. For static control experiments, cell culture was continued under static 
conditions inside suspension Petri dishes, with 8 mL supplemented cell culture medium. On 
dynamic culture, after the complete bioreactor sealing, the bioreactor reservoirs and chambers were 
placed on an incubator at 37ºC and 5% CO2. The bioreactor chambers were placed in a horizontal 
position. The peristaltic pump was set with a flow of 0.68 mL/min. This flow is in a range of 0.2 – 1 
mL/min, previously shown by Bancroft et al. [37] to induce BMSCs cell growth, proliferation and 
differentiation into the osteogenic lineage on two-dimensional cell culture conditions. The 
experiments were then carried out for 24 hours and 5 days of incubation. To remove the scaffold 
arrays from the bioreactor, the parafilm® and insulating tape shell used to seal the syringes chamber 
was cut, inside a laminar flow chamber, with a sterile scalpel. The platform was then carefully 
removed using sterile tweezers. All scaffold arrays were washed with sterile PBS, and immediately 
analyzed for cell viability. 
2.9. Live/Dead analysis 
The scaffold arrays retrieved from static and dynamic cell culture were immersed in 2 mL of sterile 
PBS containing 4 μL of calcein AM (Thermo Fisher Scientific) and 2 μL of propidium iodide (PI, 
Thermo Fisher Scientific) in the incubator at 37ºC, 5% CO2, for 30 minutes. The platforms were 
then analyzed using a fluorescence microscope (Axio Imager M2, Zeiss) with both EGFP/PI filters, 
at a fixed exposure time of 800 ms. Images were acquired in each individual spot of the platform, 
and tiled automated high-content image acquisition of whole chips was also performed. After the 
analysis, the chips were fixed with formalin at 4% (Sigma), at 4ºC, for 24 hours. The semi-
quantitative results for calcein AM signal quantification were calculated by dividing the detected 
intensity in each formulation by the one detected in the protein-free control in each individual time 
point. Higher ratios represented conditions with higher detected calcein AM signal. 
2.10. ALP quantification analysis 
After fixation with formalin, the platforms were washed twice with distilled water for 30 minutes, 
and then immersed in a ALP substract solution (1-Step™ NBT/BCIP Substrate Solution, 
ThermoScientific). The reaction took place at 37ºC, for 4 hours. The ALP present in the array was 
stained in purple. However, a method based on fluorescence analysis was developed to perform 
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rapid and easy analyses of ALP presence in each individual scaffold. Whole platform images were 
acquired automatically using a fluorescence microscope equipped with a xyz-controlled table, at an 
exposure time of 60 ms, using the EGFP filter. The whole array and scaffolds have 
autofluorescence. The places stained for ALP show a non-fluorescent signal, and black spots can be 
observed in the exact places where ALP is visibly stained. The relative semi-quantitative 
assessment of ALP per scaffold was performed by increasing the fluorescent signal of the all 
images equally, and by quantifying the fluorescent signal in each individual scaffold. Scaffolds with 
lower detected fluorescence were the ones with higher amounts of ALP. The semi-quantitative 
results for ALP quantification were calculated by dividing the detected intensity in each formulation 
by the one detected in the protein-free control. Lower ratios represented conditions with higher 
amount of detected ALP. 
3. Results and discussion   
3.1. Design of a miniaturized perfusable platform for the characterization of proteins-BMSCs 
interactions on 3D environments 
A PDMS platform with 1 mm diameter hollows and approximately 2 mm height was conceived so 
3D miniaturized porous scaffolds could be patterned inside each spot. Unlike most high-throughput 
devices, which allow physical access to biomaterials from a top view perspective, the 
homogeneously dispersed biomaterials in the platform developed here were physically accessible 
from both parallel faces of the platform (up and down sides). The possible control over PDMS 
crosslinking extent, through the application of tailored curing temperature or amount of curing 
agent, may allow the production of platforms with diversified stiffness and flexibility, which may 
allow these platforms to find application in other bioreactor settings, or in more complex design 
experiments. Also, the height, hollows’ diameter and distance may be easily tailored to achieve 
larger scaffolds models, which may later be used, for example, for in vivo implantation. 
The miniaturized freeze-dried chitosan scaffolds were covalently modified with 31 combinations of 
five proteins: fibronectin - F, vitronectin - V, collagen type-I - C, E-cadherin - E, and amelogenin – 
A; standard EDC/NHS chemistry was applied to promote the covalent reaction of chitosan amines 
groups with protein carboxylic groups [38]. One protein-free condition (chitosan only) was used as 
a control for all experiments, leading to a total of 32 total conditions studied per array. Fibronectin, 
vitronectin and collagen type-I are cell adhesive proteins present in the ECM, and are known to 
mediate cell-matrix interactions through different membrane integrins [39]. They are present in 
several human tissues, namely in bone. Amelogenin is an enamel protein that has been positively 
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associated with the osteogenic commitment of MSCs [40], and is associated with improved bone 
regeneration [41]. E-cadherin has been used to simulate cell-cell contact on biomaterials surfaces 
[42]. Initial assays performed with adsorbed protein led to cell aggregation and subsequent cell loss 
from the surface of the scaffolds after 3 days of cell culture (data not shown). Custódio et al. [36] 
showed that fibronectin immobilized onto chitosan membranes through EDC/NHS chemistry 
retains its function for a longer period than adsorbed protein.  
The combinatorial effect of cell-matrix and cell-cell interactions in osteogenic commitment of stem 
cells is still poorly studied. Previous studies have focused on the exposure of 3D encapsulated 
mesenchymal stem cells to ECM adhesive proteins and soluble growth factors [43]. The interplay of 
other types of proteins, namely cell-cell contact ones, and other aspects of bone physiology as flow 
perfusion [44] have not been undisclosed yet. The designed platform with an array of chitosan 
scaffolds allowed the study of several protein combinations simultaneously, in a time, space and 
cost-effective manner.  
3.2. Design of a perfusion bioreactor compatible with high-throughput protein-MSCs 
interactions study 
The arrayed PDMS platforms containing miniaturized chitosan scaffolds were incorporated into a 
newly designed bioreactor that allowed the continuous perfusion of each individual scaffold with 
cell culture medium, as shown in Figure 1. The bioreactor was assembled with common, affordable 
and disposable labware. Sterile disposable polypropylene syringes were used to create the main 
bioreactor chamber, which accommodated the array platform. Plastic tubes, glass bottles, HPLC 
screw caps with ports, sterile filters and one peristaltic pump were the additional material needed to 
develop the final device. The wide availability of these materials, as well as the independence from 
tailor-made pieces, facilitates the assembly of this device in any laboratory.  The bioreactor 
chamber was easily closed and isolated by using sterile parafilm and insulation tape; the use of 
micromachined chamber, O-rings and other commonly used accessories was avoided, decreasing 
costs and handling steps that may culminate in microbial contaminations of the whole setup. 
Several perfused chambers containing PDMS perforated arrayed platforms can be cultured in 
parallel by using commercially available multichannel perfusion pumps. The parallelizable nature 
of this bioreactor allows for (i) increasing time effectiveness of the experiments, because several 
independent platforms can be studied in simultaneous, (ii) the study of replicate conditions, as 
several platforms prepared under the same conditions can be simultaneously assessed using stem 
cells from controlled batches, and (iii) the effective high-throughput versatility of this system, 
because a virtually unlimited number of platforms can be studied in parallel. The diameter and 
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volume capacity of the syringes used to assemble the bioreactor chamber may be modulated, 
enabling the exposure of a different number of scaffolds to the flow perfusion conditions. This 
versatility may be useful to increase the number of studied conditions per independent experiments, 
allowing the retrieval of high amounts of experimental data in single experiments. On the contrary, 
it may be useful to limit the volume of cell culture medium necessary to perform each experiment, 
especially in the case of supplemented cell culture media with recombinant molecules, such as 
growth factors. 
The perfusion bioreactor described here was used to test 32 distinct protein-BMSCs combinations 
under a perfusion flow of 0.68 mL/minute. This flow is in the range of 0.3 to 1 mL/min, previously 
described by Bancroft et al. [45] as effective on the stimulation of the proliferation and induction of 
the osteogenic differentiation of bone marrow-derived mesenchymal stem cells.  
3.3. BMSCs in vitro response characterization 
The behavior of BMSCs while cultured on the 3D scaffold arrays was characterized using image 
analysis. The fluorescence signal intensity of calcein AM detected in each individual spot was used 
as a semi-quantitative indicator of cell number in each biomaterial. Calcein-AM is a fluorescent dye 
frequently used to evaluate cell viability. This compound enters the cell cytoplasm through the cell 
membrane, and the calcein-AM bond is broken into the two free compounds by intracellular 
esterases [46]. Free calcein remains inside viable cells with an integrate membrane, and emits a 
fluorescent signal (~515 nm), allowing the localization and detection of live cells through 
fluorescence microscopy methods. ALP is an enzyme which higher activity has been widely 
reported as an indication of early osteogenic differentiation of MSCs [47]. The loss of 
autofluorescence from the scaffolds resulting from reacted ALP was used as a semi-quantitative 
method to with the presence of the protein in each spot. All results were normalized to the protein-
free control, and they allowed to infer about the role of additive proteins to the chitosan scaffolds, 
as well as synergic effects between protein formulations and dynamic flow regime. 
 
3.4. Cell number assessment – Calcein signal quantification 
All formulations in the platforms were stained under the same conditions, and later analyzed using 
fluorescence microscopy with the same exposure time. Single images of each miniaturized spot 
were acquired for quantification purposes. Nonetheless, automated data acquisition was also 
possible using a by the Zeiss M2 microscope (Zeiss) with a controlled x-y-z table, as depicted in 
Figure 2. For image analysis, the area of the scaffolds was selected, and the image was later treated 
as a “region of interest” (ROI), in which the green fluorescence was measured directly, without any 
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image treatment, using the ZEN software (Zeiss). The ratio between the calcein signal intensity 
quantified in the protein-free spot (here, “0”) and the calcein signal intensity detected on the 
protein-containing formulations was calculated for all independent platform experiments (Figure 2). 
Figure 3 shows some of the conditions that induced promising cell response for calcein, for the 
different studied timepoints and environments and figure 4 the conditions that had lower cell 
adhesion. Figure 5 and 6 show the conditions that lead to a higher and lower ALP quantification, 
respectively. The average ratios can be found as a heatmap in Figure 7, and box plot charts showing 
medians, minimum and maximum measured values are depicted in Supplementary information- 
section C.  
 
 
Figure 2- Live/dead and ALP analysis of one array platform under flow perfusion conditions, at day 1. Live cells are 
stained in green. Cells with ALP  are black. A) Tile image acquisition of a part of the platform for Calcein. B) Tile 
image acquisition of a part of the platform for ALP. C) Amplified view of a single condition for Calcein and D) for ALP  
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After one day of cell culture under static environment, the E, EC, VE, VA, FC, VEC, FCA, VECA 
and FECA conditions showed higher calcein fluorescence signal. One of the most recurrent 
components of these mixtures is the cell-adhesive proteins type I collagen, which is present in the 
human native ECM [48]. The presence of collagen in the chitosan scaffolds by itself, however, was 
not enough to trigger a higher cell number in the scaffolds as compared to the protein-free control 
(Figure 7). Another protein with high predominance in the formulations that elicited higher calcein 
signal was E-cadherin. E-cadherin is responsible for calcium-dependent cell-cell adhesion [49], and 
biologically it is known to be present in cells from the epithelial lineage, such as epithelial stem 
cells (ESCs) [50]. For biomaterial-modification purposes, it has been suggested as a component of 
biomaterials capable of inducing MSCs proliferation and inhibiting apoptosis [51]. E-cadherin is 
involved in cell adhesion, proliferation, migration and differentiation [52], and its function is 
reported to go beyond the establishment of cell-cell junctions; it is known that it takes part in 
signaling pathways, including the Rho GTPase signaling [53,54]. Here, the modification of chitosan 
scaffolds with E-cadherin alone was enough to detect a higher calcein signal. When allied with cell 
adhesion proteins (mainly collagen and vitronectin), E-cadherin showed improved cell adhesion 
capacity: its conjugation with ECM integrin-mediated adhesive proteins, namely vitronectin, 
fibronectin and collagen showed also an increased ability to promote cell attachment (Figure 7). 
The mixture of E-cadherin with ECM adhesive proteins was effective on binary, ternary and 
quaternary combinations, indicating that the proteins kept their function even in lower proportion in 
the formulations. In general, initial MSCs adhesion to chitosan scaffolds seems to be enhanced in 
combinatorial protein combinations, instead of single protein formulations. ECM adhesive proteins 
and E-cadherin, also in the presence of amelogenin in certain formulations, seem to have a 
synergistic effect on this phenomenon. After 5 days under static conditions, the platform spots 
showing increased calcein signal when compared to the protein-free conditions were the following:  
EA, VC, FEC, FEA, FVE, ECA, VECA, FVEA. As observed at day 1, conditions with the 
combination of fibronectin, vitronectin, E-cadherin and amelogenin promote a higher number of 
adherent cells (Figure 7).  
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Figure 3- Examples of conditions with higher calcein values, for the different studied environments and timepoints. 
A),B),C) Replicates of FECA for day 1, static environment. D), E), F) Replicates of FEC for day 5, static environment. G), 
H), I) Replicates of FECA for day 1, dynamic environment. J), L), M) Replicates of VEA for day 5, dynamic 
environment.  
The analysis of calcein fluorescence intensity for platforms cultured under dynamic conditions 
(Figure 7) showed that after 1 day of cell culture the conditions with highest calcein signal were F, 
A, VEC, VEA, FVCA and FECA. The interaction between ECM adhesive proteins, along with E-
cadherin and amelogenin, seem to dictate higher cell adhesion. The recurrent presence of 
amelogenin in these formulations may indicate a correlation between this cell adhesion protein [55] 
and mechanotransduction phenomenon observed in the dynamic conditions assays. For 5 days of 
cell culture under dynamic flow stimulation, FA, FC and, FEA, VEC and VEA conditions showed 
the highest calcein intensity. As observed on previous time points, specific conditions with 
interactions between adhesive proteins (as fibronectin and vitronectin) with E-cadherin and 
amelogenin promote a higher number of adhered live cells in the scaffolds. Statistical analysis of 
effects of each individual protein or groups of proteins on the calcein signal detected in each 
scaffold shows that on all time points amelogenin shows a general positive effect on the number of 
cells present in the scaffold (Figure 7). After 5 days of static culture, the presence of amelogenin 
and E-cadherin in the protein mixtures are the major driving forces for increased cell number 
(Figure 7). In opposition to static culture, the effect of vitronectin alone on protein formulations was 
robust enough to be shown on the effect list, both for day 1 and day 5 of cell culture (Figure 7). 
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Interactions of E-cadherin and adhesive proteins also contributed significantly for increased cell 
number.  
Although the integrin-mediated interactions between cells and ECM proteins as fibronectin, 
vitronectin and type I collagen are widely reported [56], the specific cell interaction mechanism of 
amelogenin is still yet not fully understood. A study made by Kirkham et al., showed that 
amelogenin interacts with cells through the cell membrane [57]. Lokappa et al. later showed that 
this interaction was made at the membrane phospholipids [58], and that the N-terminal of 
amelogenin may be the responsible for this interaction, since enamel malformations of the 
amelogenin’s N-terminal in the disease amelogenesis imperfecta (AI) lead to a faulty interaction 
between cells and the protein [59]. The improving effect of amelogenin on the cell number in the 
scaffolds, both on static and dynamic culture conditions, may be related to its adhesive interactions 
with cells through mechanisms that differ from the other proteins. Another possibility to explain the 
adjuvant effect observed relies on the possible configurational and structural alterations that 
amelogenin may induce in other proteins present in the mixtures used to modify the surface of the 
chitosan scaffolds. Protein-protein interactions have been reported to induce structural and 
functional changes in different combinations of proteins [60-62]. The interaction of each protein 
with different cell types also dictates the role of each protein. In a particular example, Heydarkhan-
Hagvall et al. reported that scaffolds coated in vitronectin showed higher cell adhesion rates of 
embryonic stem cells, other than those coated in fibronectin, on a 3D environment [63].  
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Figure 4- Examples of conditions with lower calcein values, for the different studied environments and timepoints. 
A),B),C) Replicates of V for day 1 static environment. D), E), F) Replicates of F for day 5 static environment. G),H), I) 
Replicates of FA for day 1 dynamic environment. J), L), M) Replicates of A for day 5, dynamic environment. 
3.5. ALP quantification analysis 
An innovative approach was developed to assess the amount of ALP in each individual spot of the 
platforms. After the enzyme-substrate reaction, ALP in the platforms was stained with a purple 
color. Under the green fluorescent beam used to analyze calcein signal, the ALP stained cells 
(figure 2 D) emit a non-fluorescent signal, while by increasing the lamp’s exposure time, the 
chitosan scaffolds showed green autofluorescence (Figure 7). Pictures of the whole platform were 
acquired using a fixed exposure time, and the lowering of the fluorescence values in each spot was 
inversely correlated with the presence of ALP.  
After one day of static cell culture, the conditions that led higher ALP quantification were: FV, FE, 
VA, ECA and FVEC. For this timepoint and under static conditions, none of the proteins alone led 
to an increase on ALP quantification (Figure 7). Amelogenin has been reported as capable of 
inducing osteogenic differentiation of embryonic stem cells through the activation of the Wtn 
pathway [64]. E-cadherin was also high predominant in the mixtures triggering higher ALP levels 
(Figure 7). Despite different mesenchymal cadherins are known to mediate bone formation in vivo 
[65], the role of E-cadherin has not been disclosed yet. Despite its role as an individual protein has 
not induced an increase in ALP quantification, here we observed that its mixture with ECM 
adhesive proteins as fibronectin and collagen has led to improved effects.  
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After 5 days of cell culture under static conditions, ALP quantification levels were, in general, 
lower than at day 1, as compared to the protein-free control (Figure 7). The major positive effects 
on ALP quantification were observed in the conditions FV and FVA. For this timepoint, fibronectin 
clearly has a pronounced effect, as it appears several times on the conditions leading ALP increased 
expression. Tang et al., verified that human plasma fibronectin coated on scaffold surfaces 
enhanced odontoblast-like cells proliferation, differentiation and mineralization [66]. Conditions 
containing both vitronectin and amelogenin also led increased ALP quantification. Despite type I 
collagen has previously shown adjuvant effects on osteogenic differentiation of MSCs [67], this 
effect was not observed here, which may be related to the porous scaffolds system developed here, 
and/or with the interactions established in the protein mixtures leading to functional loss of each 
individual protein. Despite their ability to trigger osteogenic differentiation of BMSCs, different 
proteins have been proved to act through different pathways. For example, adult mesenchymal stem 
cells were grown in 2D substrates treated with adsorbed vitronectin and type I collagen [68], and 
osteogenesis on vitronectin correlated with enhanced focal adhesion formation, the activation of 
focal adhesion kinase (FAK) and paxillin, and the diminished activation of extracellular signal-
regulated kinase (ERK) and phosphatidylinositol-3 kinase (PI3K) pathways. On type-I collagen, the 
osteogenic differentiation occurred with lower focal adhesion formation, reduced activation of FAK 
and paxillin, and increased activation of ERK and PI3K). The simultaneous stimulation of different 
pathways in combinatorial biomaterial formulations, along with 3D culture conditions (in 
opposition to conventionally used 2D platforms) may hide the cues to explain the complex results 
observed in the studied array. 
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Figure 5- Examples of conditions with higher ALP values, for the different studied environments and timepoints. 
A),B),C) Replicates of FA for day 1, static environment. D), E), F) Replicates of FV for day 5, static environment. G), 
H), I) Replicates of E for day 1, dynamic environment. J), L), M) Replicates of FECA for day 5, dynamic environment. 
After one day under flow, the formulations A, E, FA, VC, ECA, and FECA led the highest 
expressions of ALP (Figure 7). Here, the effect of amelogenin alone and in combination with other 
conditions is visible, and was statistically detected on the effect assessment (Figure 7). Conditions 
that promoted the highest osteogenic pathway response indicate a possibly positive effect of 
collagen in coordination with amelogenin in the dynamic flow conditions, in opposition to the static 
culture setup, in which collagen did not show any adjuvant effect on the osteogenic induction of 
BMSCs. The relevance of amelogenin in this process is evidenced by, for example, analyzing cell 
response to EC composition, which rendered one of the lowest ALP quantification ratios, in 
opposition to the highly ALP inducing ECA. 
The adjuvant and predominant effect of amelogenin and some of its combinations is visible after 5 
days of cell culture in the bioreactor (Figure 7). The highest ALP quantification was observed for 
VE. FA, ECA, FVA and FECA conditions. In a similar way to the observations on static conditions, 
fibronectin in combination with other proteins shows a relevant role after 5 days of cell culture, in 
opposition to day 1, in which its presence does not lead the increase of ALP quantification. In 
accordance with the results from day 1, the presence of amelogenin in the hit spotted formulations 
is observed, and this trend is visible in the effect list (Figure 7). 
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In summary, after one day of cell culture higher ALP quantification seems to be dictated, both on 
static and dynamic conditions, by formulations rich in either amelogenin and/or E-cadherin in 
combination with ECM proteins as fibronectin and vitronectin. At day 5, the role of fibronectin is 
more preponderant, which is probably associated with the ability of this protein to induce cell 
adhesion and proliferation when covalently immobilized in chitosan substrates [36]. On the 
dynamic culture conditions, the presence of amelogenin seems to promote an enhanced pre-
osteogenic commitment, indicating a possible synergic relationship between the protein and the 
applied flow. 
 
 
 
Figure 6- Examples of conditions with lower ALP values, for the different studied environments and timepoints. 
A),B),C) Replicates of V for day 1, static environment. D), E), F) Replicates of EC for day 5, static environment. G), H), 
I) Replicates of EC for day 1, dynamic environment. J), L), M) Replicates of FE for day 5, dynamic environment. 
The comparison of the ALP quantification trends (Figure 7) with the normalized ALP ratios by 
calcein intensity ratios (Figure 7) shows similar results. This indicates that, in the case of the 
analysis conducted in this study, the total cell amount in each biomaterial did not influence the 
comparative amounts of ALP and, consequently, the respective analysis. 
Biomaterials application targeting rapid tissue regeneration may benefit from improved cell number 
attached to the scaffold, along with a rapid triggering of a desired differentiation response. The 
identification of biomaterials formulations and culture conditions that withstand both high cell 
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number and high ALP quantification are shown in Supplementary Information, section A and B, 
inside the dashed rectangles. A threshold of calcein ratio above 1.1 and ALP below 0.8 (given that 
lower ALP ratios correspond to higher amount of the protein present in the scaffolds) was set. Flow 
perfused conditions allowed assessing a higher number of formulations enabling both high cell 
number and ALP activity, as compared to static conditions.  
The technology developed in this work allowed the affordable and rapid assessment of protein-
BMSCs interactions under static and dynamic flow perfusion conditions. Although protein 
combinations and cell suspensions were dispensed in each individual platform spot manually, the 
flat configuration and precise array position of the 3D scaffolds in the developed chips make them 
compatible with the use of automatized robots, commonly used in the preparation of high-
throughput devices. The analysis performed in this work was based on the assessment of early 
markers of osteogenesis. We envision the further use of the developed system on long-term studies 
targeting osteogenesis and other tissue regeneration pathways. The versatility of the method makes 
it a potential device for the future testing of more protein and surface-modification molecules, along 
with other cell types, driving new discoveries in the fields of biomaterials development for tissue 
regeneration, drug discovery and disease models design. 
 
Figure 7- Heatmaps of the average ratio values obtained by dividing the acquired calcein AM or ALP signal for each 
condition by the value of the protein-free condition in that time point (here, condition “0”). Higher values are 
represented in red. All values were acquired in sets of 5 to 8 independent experiments. Due to sample loss that 
occurred mainly after formalin fixation of the platforms (probably due to shrinkage of the chitosan scaffolds and 
subsequent loss to the medium), all samples represented in this heatmap are the mean value of, at least, 3 scaffolds 
and, maximum, 8 scaffolds. 
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4. Conclusion 
In this work, an arrayed hollow platform was developed to incorporate 3D porous biomaterials that 
were modified with 32 different combinations of proteins present in bone ECM, cell-cell contact 
junctions and enamel. The interactions between each individual biomaterial combination and human 
BMSCs were tested under static cell culture conditions, as well as under a dynamic perfusion flow. 
A bioreactor was assembled using widely available labware, based mainly on disposable plastic 
material. Two syringes were assembled to work as a chamber in which the developed arrayed 
platform was incorporated. The system allowed different flows, controlled through the movement of 
a peristaltic pump. A high-throughput study was performed by testing 32 biomaterials-cells 
interactions in a single platform. By using a programmable table with controlled xyz positioning, 
images of the whole platforms could be acquired in a single automatized step. Image analysis was 
used to establish comparisons of cell number in each biomaterial condition, and of the expression of 
an osteogenic early marker: alkaline phosphatase. The results obtained in this study, with 64 
conditions assessed per time point, allowed concluding about the importance of multiprotein 
formulations on the triggering of cell adhesion and osteogenic commitment of BMSCs. Hit-spotted 
formulations leading to high cell adhesion and ALP quantification consisted of mixtures of ECM-
adhesive proteins (namely, fibronectin, type-I collagen and vitronectin) with cell-cell contact 
proteins (E-cadherin) and, with a high consistency, amelogenin. Cell response and hit-spotted 
biomaterial formulations were dependent on the application of flow perfusion on the whole system, 
and the application of dynamic flow drove cells to express high amounts of ALP as compared to 
protein-free conditions. This proof-of-concept work allowed proving the potential of the developed 
high-throughput system to test cell-biomaterials interactions under flow. Each component of the 
bioreactor shows versatility, which opens the possibility of testing a higher number of biomaterials 
per independent experiment, patterning biomaterials with distinct shapes and sized (by modulating 
the hollows of the array platform), and exposing the system to distinct flows. Also, different cell 
types (and even co-culture setups) and biomaterials combinations are amenable to be tested in 
future works using this platform, which makes it an appealing tool to be used for novel 
breakthrough discoveries on healthcare fields, including regenerative medicine, drug discovery and 
disease model/organ-on-a-chip development.  
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1. Conclusion and Future work 
The high complexity associated with bone’s physiology is an important factor driving the difficult 
regeneration of this tissue after trauma. Bone defects are capable of healing by themselves on small-
scale injuries. However, severe damage leading to defects with diameters larger than 2 cm show 
impaired self-healing ability. To achieve fully functional bone regenerative therapies, it is necessary 
to understand the individual distinctive biological processes and structural features of bone biology. 
Bone must not be overlooked as a dynamic and complex system in which highly regulated crosstalk 
occurs. In this study, we suggest the development of a perfusion bioreactor for the high-throughput 
analysis of several protein combinations and their effect on human BMSCs response under flow 
perfusion. The studied protein array comprised bone ECM, cell-cell contact junction and enamel 
proteins. We created an arrayed hollow platform, developed to incorporate 3D porous biomaterials 
modified with 32 different combinations of proteins. A bioreactor was assembled using widely 
available labware, based mainly on disposable plastic material. Two syringes were assembled to 
work as a chamber in which the developed arrayed platform was incorporated. The system is 
versatile to allow the application of different flows, simply controlled through the movement of a 
peristaltic pump. By using a programmable table with controlled xyz positioning, images of the 
whole platforms could be acquired in a single automatized step. Image analysis was used to 
establish comparisons of cell number in each biomaterial condition, and of the expression of an 
osteogenic early marker: alkaline phosphatase (ALP). The results obtained in this study, with 64 
conditions assessed per time point allowed concluding about the importance of multiprotein 
formulations on the triggering of cell adhesion and osteogenic commitment of BMSCs, and their 
combined role with dynamic flow stimulation. Hit-spotted formulations leading to high cell 
adhesion and ALP quantification consisted of mixtures of ECM-adhesive proteins (namely, 
fibronectin, type-I collagen and vitronectin) with cell-cell contact proteins (E-cadherin) and, with a 
high consistency, amelogenin. Cell response was highly dependent on the application of flow 
perfusion, which showed synergic effects with different protein combinations. 
The present work has shown the potential of a novel perfusion bioreactor for applications on 
healthcare field, namely for the development of regenerative medicine in vitro systems. The 
developed system provided the implementation of high-throughput analysis of biomaterials 
targeting bone regeneration through the use of bone and enamel microenvironment proteins. 
The most relevant novelty associated with the developed device is associated with the ability 
to locally induce mechanical stimuli to cells cultured in 3D scaffolds, in a mimetic approach 
of the native bone flow perfusion. In vivo, such mechanical stimulation is crucial to enable 
healthy bone maintenance and to induce healing. Despite the potential of the developed 
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system for tissue regeneration, the work developed here was a proof-of-concept targeting 
osteogenic stem cell differentiation on early time points (5 days of cell culture). The 
application of this system for time points targeting mature osteogenic differentiation, such as 
21 days of cell culture, is a needed step in future work.  Moreover, only chitosan 3D scaffolds 
were studied, as well as fixed proportions of proteins.  The potential of this high-throughput 
platform for the study of larger arrays of biomaterials (processed with different techniques 
and with distinct features), cells and co-cultures under perfused environment, with different 
perfusion flows in discrete/continuous mode, would allow to prove the full potential of the 
developed bioreactor as a high-throughput versatile device for tissue regeneration, or even for 
disease model studies.  
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A- Detailed fluorescence images of calcein, for the several conditions and timepoints 
 
 
Figure A1- Fluorescence of 3 replicates of E condition for static environment day 1 
 
Figure A2- Fluorescence of 3 replicates of FC condition for static environment day 1 
 
Figure A3- Fluorescence of 3 replicates of VE condition for static environment day 1 
 
Figure A4- Fluorescence of 3 replicates of VA condition for static environment day 1 
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Figure A5- Fluorescence of 3 replicates of EC condition for static environment day 1 
 
 
Figure A6- Fluorescence of 3 replicates of FCA condition for static environment day 1 
 
Figure A7- Fluorescence of 3 replicates of VEC condition for static environment day 1 
 
Figure A8- Fluorescence of 3 replicates of VECA condition for static environment day 1 
 
Figure A9- Fluorescence of 3 replicates of FECA condition for static environment day 1 
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Figure A10- Fluorescence of 3 replicates of VC condition for static environment day 5 
 
Figure A11- Fluorescence of 3 replicates of EA condition for static environment day 5 
 
Figure A12- Fluorescence of 3 replicates of FVE condition for static environment day 5 
 
 
Figure A13- Fluorescence of 3 replicates of FEC condition for static environment day 5 
 
 
Figure A14- Fluorescence of 3 replicates of FEA condition for static environment day 5 
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Figure A15- Fluorescence of 3 replicates of ECA condition for static environment day 5 
 
 
Figure A16- Fluorescence of 3 replicates of FVEA condition for static environment day 5 
 
Figure A17- Fluorescence of 3 replicates of VECA condition for static environment day 5 
 
Figure A18- Fluorescence of 3 replicates of FECA condition for dynamic environment day 1 
 
 
Figure A19- Fluorescence of 3 replicates of VECA condition for dynamic environment day 1 
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Figure A20- Fluorescence of 3 replicates of FVCA condition for dynamic environment day 1 
 
 
Figure A21- Fluorescence of 3 replicates of FA condition for dynamic environment day 5 
 
 
Figure A22- Fluorescence of 3 replicates of VE condition for dynamic environment day 5 
 
 
Figure A23- Fluorescence of 3 replicates of VEA condition for dynamic environment day 5 
 
 
Figure A 24- Fluorescence of 3 replicates of V condition for static environment day 1 
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Figure A25- Fluorescence of 3 replicates of FE condition for static environment day 1 
 
 
Figure A26- Fluorescence of 3 replicates of FVEA condition for static environment day 1 
 
 
Figure A27- Fluorescence of 3 replicates of F condition for static environment day 5 
 
 
Figure A28- Fluorescence of 3 replicates of V condition for static environment day 5 
 
 
Figure A29- Fluorescence of 3 replicates of FVECA condition for static environment day 5 
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Figure A30- Fluorescence of 3 replicates of FA condition for dynamic environment day 1 
 
 
Figure A31- Fluorescence of 3 replicates of FV condition for dynamic environment day 1 
 
 
Figure A32- Fluorescence of 3 replicates of VCA condition for dynamic environment day 1 
 
 
Figure A33- Fluorescence of 3 replicates of A condition for dynamic environment day 5 
 
 
Figure A34- Fluorescence of 3 replicates of FE condition for dynamic environment day 5 
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Figure A35- Fluorescence of 3 replicates of VCA condition for dynamic environment day 5 
 
 
Figure A36- Fluorescence of 3 replicates of the condition with no proteins (control) 
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B- Detailed fluorescence images of ALP conditions for the several timepoints and different 
environments 
 
Figure B1- Fluorescence of 3 replicates of FE condition for static environment day 1 
 
Figure B2- Fluorescence of 3 replicates of VA condition for static environment day 1 
 
Figure B3- Fluorescence of 3 replicates of ECA condition for static environment day 1 
 
Figure B4- Fluorescence of 3 replicates of FVEC condition for static environment day 1 
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Figure B5- Fluorescence of 3 replicates of V condition for static environment day 1 
 
Figure B6- Fluorescence of 3 replicates of C condition for static environment day 1 
 
Figure B7- Fluorescence of 3 replicates of VE condition for static environment day 5 
 
Figure B8- Fluorescence of 3 replicates of ECA condition for static environment day 5 
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Figure B9- Fluorescence of 3 replicates of FVA condition for static environment day 5 
 
Figure B10- Fluorescence of 3 replicates of FECA condition for static environment day 5 
 
Figure B11- Fluorescence of 3 replicates of FVC condition for static environment day 5 
 
Figure B12- Fluorescence of 3 replicates of EC condition for static environment day 5 
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Figure B13- Fluorescence of 3 replicates of ECA condition for dynamic environment day 1 
 
Figure B14- Fluorescence of 3 replicates of FECA condition for dynamic environment day 1 
 
Figure B15- Fluorescence of 3 replicates of A condition for dynamic environment day 1 
 
Figure B16- Fluorescence of 3 replicates of FA condition for dynamic environment day 1 
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Figure B17- Fluorescence of 3 replicates of FC condition for dynamic environment day 1 
 
Figure B18- Fluorescence of 3 replicates of EC condition for dynamic environment day 1 
 
Figure B19- Fluorescence of 3 replicates of FA condition for dynamic environment day 5 
 
Figure B20- Fluorescence of 3 replicates of ECA condition for dynamic environment day 5 
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Figure B21- Fluorescence of 3 replicates of FVA condition for dynamic environment day 5 
 
Figure B22- Fluorescence of 3 replicates of FECA condition for dynamic environment day 5 
 
Figure B23- Fluorescence of 3 replicates of FVEC condition for dynamic environment day 5 
 
Figure B24- Fluorescence of 3 replicates of FE condition for dynamic environment day 5 
 
Figure B25- Fluorescence of 3 replicates of the condition with no proteins (control) 
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C- Plot box for the calcein and ALP data 
 
Figure C1- Box plot for calcein data, for the several timepoints and environments 
 
 
Figure C2- Boxplot for ALP, for the several conditions and timepoints 
 
 
 
 
120 
 
D- Cluster graphics  
 
 
Figure D1- Cluster graphics for the evaluation of calcein/ALP. Relevant conditions are the ones that fall on an area 
which ALP value is under 0,8 and calcein over 1,1.  
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E- Effects of the several conditions  
 
 
Figure E1- Calcein effects of the several conditions for all the timepoints. In here we can see which conditions induce 
a better response for cell adhesion.  
 
 
Figure E2- ALP effects of the several conditions for all the timepoints. In here we can see which conditions induce a 
better response for osteogenic pathway induction.  
 
 
 
 
 
